0001164888
false
--03-31
2022
Q3
0001164888
2021-04-01
2021-12-31
0001164888
2022-02-18
0001164888
2021-12-31
0001164888
2021-03-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-03-31
0001164888
us-gaap:SeriesBPreferredStockMember
2021-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2021-03-31
0001164888
2021-10-01
2021-12-31
0001164888
2020-10-01
2020-12-31
0001164888
2020-04-01
2020-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredAStockClassAOneATwoMember
2021-09-30
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-09-30
0001164888
us-gaap:RetainedEarningsMember
2021-09-30
0001164888
2021-09-30
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredAStockClassAOneATwoMember
2021-10-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-10-01
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-10-01
2021-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-10-01
2021-12-31
0001164888
us-gaap:RetainedEarningsMember
2021-10-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredAStockClassAOneATwoMember
2021-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001164888
us-gaap:RetainedEarningsMember
2021-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredAStockClassAOneATwoMember
2021-03-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-03-31
0001164888
us-gaap:CommonStockMember
2021-03-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-03-31
0001164888
us-gaap:RetainedEarningsMember
2021-03-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredAStockClassAOneATwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2021-04-01
2021-12-31
0001164888
us-gaap:RetainedEarningsMember
2021-04-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-09-30
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2020-09-30
0001164888
us-gaap:CommonStockMember
2020-09-30
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-09-30
0001164888
us-gaap:RetainedEarningsMember
2020-09-30
0001164888
2020-09-30
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-10-01
2020-12-31
0001164888
us-gaap:RetainedEarningsMember
2020-10-01
2020-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-12-31
0001164888
us-gaap:RetainedEarningsMember
2020-12-31
0001164888
2020-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-03-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2020-03-31
0001164888
us-gaap:CommonStockMember
2020-03-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-03-31
0001164888
us-gaap:RetainedEarningsMember
2020-03-31
0001164888
2020-03-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesAPreferredStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:PreferredStockMember
us-gaap:SeriesBPreferredStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:AdditionalPaidInCapitalMember
2020-04-01
2020-12-31
0001164888
us-gaap:RetainedEarningsMember
2020-04-01
2020-12-31
0001164888
KBPH:PreferredBStockBClassBOneBTwoBThreeMember
2021-12-31
0001164888
KBPH:PreferredBStockClassBOneBThreeMember
2021-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2020-12-31
0001164888
KBPH:AbferoPharmaceuticalsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSidecarTwentyFivePercentageDiscountNoInterestMember
2021-12-31
0001164888
KBPH:AOADXIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember
2021-12-31
0001164888
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2021-12-31
0001164888
KBPH:BasepawsIncOneMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember
2021-12-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:ColabsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2021-12-31
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember
2021-12-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteZeroPercentageOnDueDateMember
2021-12-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoOneMember
2021-12-31
0001164888
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:FemtoDXIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeOneMember
2021-12-31
0001164888
KBPH:IrisRAndDGroupIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-12-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-12-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2021-12-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageNoDueDateMember
2021-12-31
0001164888
KBPH:MMTronIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:NavauxIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueNovemberTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2021-12-31
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueMayTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeOnlyMember
2021-12-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:RheosIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember
2021-12-31
0001164888
KBPH:SaccharoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2021-12-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2021-12-31
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedMember
2021-12-31
0001164888
KBPH:SensingElectromagneticPlusCorpMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFullyReservedOneMember
2021-12-31
0001164888
KBPH:ShyftMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:SinglePassIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember
2021-12-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2021-12-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2021-12-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:US
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
country:CA
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-12-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2021-12-31
0001164888
KBPH:ColabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-12-31
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:DistasenseIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesCPreferredStockMember
2021-12-31
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:HealionicsCorporationMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-12-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2021-12-31
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:KitotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredMember
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-12-31
0001164888
KBPH:MakaniScienceIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:NanochonIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-12-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-12-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-12-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredOneMember
2021-12-31
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:PartheousIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredMember
2021-12-31
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2021-12-31
0001164888
KBPH:TrioLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-12-31
0001164888
KBPH:VesteckIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-12-31
0001164888
KBPH:PreferredInvestmentsMember
2021-12-31
0001164888
KBPH:PreferredInvestmentsMember
country:US
2021-12-31
0001164888
KBPH:PreferredInvestmentsMember
country:CA
2021-12-31
0001164888
KBPH:PreferredInvestmentsMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-12-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-12-31
0001164888
KBPH:KuantsolIncMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-12-31
0001164888
KBPH:CommonStockInvestmentMember
2021-12-31
0001164888
KBPH:CommonStockInvestmentsMember
country:US
2021-12-31
0001164888
KBPH:CommonStockInvestmentsMember
country:CA
2021-12-31
0001164888
KBPH:CommonStockInvestmentsMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:CommonStockInvestmentsMember
2021-12-31
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:PublicCommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-12-31
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:PublicCommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-12-31
0001164888
KBPH:SanabyHealthAcquisitionCorpOneMember
KBPH:LifeScienceMember
KBPH:PublicCommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-12-31
0001164888
KBPH:PublicCommonStockInvestmentMember
2021-12-31
0001164888
KBPH:PublicCommonStockInvestmentsMember
country:US
2021-12-31
0001164888
KBPH:PublicCommonStockInvestmentsMember
country:CA
2021-12-31
0001164888
KBPH:PublicCommonStockInvestmentsMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:PublicCommonStockInvestmentsMember
2021-12-31
0001164888
KBPH:AOADXIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-12-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeTwoMember
2021-12-31
0001164888
KBPH:MadorraIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-12-31
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:PolymertalIncMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:SafeInvestmentsMember
2021-12-31
0001164888
KBPH:SafeInvestmentsMember
country:US
2021-12-31
0001164888
KBPH:SafeInvestmentsMember
country:CA
2021-12-31
0001164888
KBPH:SafeInvestmentsMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-12-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2021-12-31
0001164888
KBPH:ExodosLifeSciencesLPMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsThreeMember
2021-12-31
0001164888
KBPH:RisoCapitalFundILPMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:OwnershipUnitsMember
2021-12-31
0001164888
KBPH:RisoCapitalFundILPMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:OwnershipUnitsOneMember
2021-12-31
0001164888
KBPH:OtherInvestmentMember
2021-12-31
0001164888
KBPH:OtherInvestmentMember
country:US
2021-12-31
0001164888
KBPH:OtherInvestmentMember
country:CA
2021-12-31
0001164888
KBPH:OtherInvestmentMember
KBPH:RestOfWorldMember
2021-12-31
0001164888
country:US
2021-12-31
0001164888
country:CA
2021-12-31
0001164888
KBPH:RestOfWorldMember
2021-12-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AcheliosTherapeuticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AcheliosTherapeuticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AcheliosTherapeuticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AvisiTechnologiesIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CorinnovaIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteZeroPercentageOnDueDateMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:DeepBlueMedicalAdvancesIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:EveryKeyIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:IdenticalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KianaAnalyticsMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NavauxIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NeuroFoutyTwoIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:PerikineticsIncMember
2021-03-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
2021-03-31
0001164888
KBPH:ConvertibleNoteFullyReservedMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SensingElectromagneticPlusCorpMember
2021-03-31
0001164888
KBPH:ConvertibleNoteFullyReservedOneMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SensingElectromagneticPlusCorpMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ValfixMedicalIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:XpanIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
2021-03-31
0001164888
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
2021-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
country:US
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
country:CA
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
KBPH:RestOfWorldMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:AltisBiosystemsMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:AstrocytePharmaceuticalsIncMember
2021-03-31
0001164888
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
KBPH:CnoteGroupIncMember
2021-03-31
0001164888
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
KBPH:CnoteGroupIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:ColabsIncMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:ConnectusServicesLtdMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:DeepBlueMedicalAdvancesIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:EumentisThereapeuticsIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:FemtoDXIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
KBPH:ILumenScientificIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
KBPH:ILumenScientificIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:InhalonBiopharmaIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:LightLineMedicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
KBPH:LightLineMedicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:LightLineMedicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
KBPH:LightLineMedicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:LowellTherapeuticsIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
KBPH:LowellTherapeuticsIncMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
KBPH:MicronicTechnologiesIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
KBPH:NeuroflowIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
KBPH:NeuroflowIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:NewViewSurgicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
KBPH:OtomagneticsIncMember
2021-03-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:SealRockTherapeuticsIncMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:ShyftFKACraterGroupIncMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
KBPH:ShyftFKACraterGroupIncMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
KBPH:ShyftFKACraterGroupIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
KBPH:TrellisBioscienceLLCMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
KBPH:TrellisBioscienceLLCMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
KBPH:TrellisBioscienceLLCMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:ValfixMedicalIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
KBPH:VisgenxIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:VisgenxIncMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
KBPH:VisgenxIncMember
2021-03-31
0001164888
KBPH:PreferredInvestmentsMember
2021-03-31
0001164888
country:US
KBPH:PreferredInvestmentsMember
2021-03-31
0001164888
country:CA
KBPH:PreferredInvestmentsMember
2021-03-31
0001164888
KBPH:RestOfWorldMember
KBPH:PreferredInvestmentsMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
KBPH:BendaRXCorpMember
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
KBPH:BendaRXCorpMember
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
KBPH:BoardwalkTechMember
2021-03-31
0001164888
KBPH:CommonStockInvestmentsMember
2021-03-31
0001164888
country:US
KBPH:CommonStockInvestmentsMember
2021-03-31
0001164888
country:CA
KBPH:CommonStockInvestmentsMember
2021-03-31
0001164888
KBPH:RestOfWorldMember
KBPH:CommonStockInvestmentsMember
2021-03-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:InfinidomeLtdMember
KBPH:TechnologyMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-03-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:MitreMedicalCorpMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeOneMember
2021-03-31
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:SafeInvestmentsMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:SafeInvestmentsMember
2021-03-31
0001164888
country:US
KBPH:SafeInvestmentsMember
2021-03-31
0001164888
country:CA
KBPH:SafeInvestmentsMember
2021-03-31
0001164888
KBPH:RestOfWorldMember
KBPH:SafeInvestmentsMember
2021-03-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-03-31
0001164888
KBPH:SeriesAOneOwnershipUnitsOneMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:EnduralockLLCMember
2021-03-31
0001164888
KBPH:ExodosLifeSciencesLPMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2021-03-31
0001164888
KBPH:OwnershipUnitsMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:RisoCapitalFundILPMember
2021-03-31
0001164888
KBPH:OtherInvestmentMember
2021-03-31
0001164888
country:US
KBPH:OtherInvestmentMember
2021-03-31
0001164888
country:CA
KBPH:OtherInvestmentMember
2021-03-31
0001164888
KBPH:RestOfWorldMember
KBPH:OtherInvestmentMember
2021-03-31
0001164888
country:US
2021-03-31
0001164888
country:CA
2021-03-31
0001164888
KBPH:RestOfWorldMember
2021-03-31
0001164888
KBPH:AbferoPharmaceuticalsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemeberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2021-04-01
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AOADXIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFourPercentageDueMayTwoThousandTwentyFourMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2021-04-01
2021-12-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember
2021-12-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueOctoberTwoThousandThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ColabsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:FemtoDXIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyThreeOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:IrisRAndDGroupIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteEightPercentageDueMayTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:MMTronIncMember
KBPH:TechnologyMember
KBPH:ConvertibleNoteFourPercentageDueAprilTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NavauxIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueNovemberTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2021-04-01
2021-12-31
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueMayTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-12-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJulyTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:RheosIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAugustTwoThousandTwentySixMember
2021-04-01
2021-12-31
0001164888
KBPH:SaccharoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueSeptemberTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ShyftMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyThreeMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:SinglePassIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteSixPercentageAprilTwoThousandTwentyFourMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2021-04-01
2021-12-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-12-31
0001164888
us-gaap:CorporateNoteSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2021-04-01
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:XpanIncMember
KBPH:LifeScienceMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2021-04-01
2021-12-31
0001164888
KBPH:AltisBiosystemsMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:AstrocytePharmaceuticalsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:CnoteGroupIncMember
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:ColabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:ConnectusServicesLtdMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:DistasenseIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:EumentisThereapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:FemtoDXIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:HealionicsCorporationMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:ILumenScientificIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
2021-04-01
2021-12-31
0001164888
KBPH:InhalonBiopharmaIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:KitotechMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-04-01
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:LightLineMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
2021-04-01
2021-12-31
0001164888
KBPH:LowellTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:MakaniScienceIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:MicronicTechnologiesIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:NeuroflowIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:NewViewSurgicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredOneMember
2021-04-01
2021-12-31
0001164888
KBPH:OrionBiotechnologyIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:OtomagneticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:PartheousIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:SealRockTherapeuticsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:ShyftFKACraterGroupIncMember
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
2021-04-01
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
2021-04-01
2021-12-31
0001164888
KBPH:TrellisBioscienceLLCMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:TrioLabsIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
2021-04-01
2021-12-31
0001164888
KBPH:VesteckIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
2021-04-01
2021-12-31
0001164888
KBPH:VisgenxIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
2021-04-01
2021-12-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
KBPH:BendaRXCorpMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-04-01
2021-12-31
0001164888
KBPH:KuantsolIncMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:PublicCommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:PublicCommonStockInvestmentsMember
KBPH:CommonStockOneMember
2021-04-01
2021-12-31
0001164888
KBPH:SanabyHealthAcquisitionCorpOneMember
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsMember
2021-04-01
2021-12-31
0001164888
KBPH:EnduralockLLCMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:SeriesAOneOwnershipUnitsOneMember
2021-04-01
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsMember
2021-04-01
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
2021-04-01
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
2021-04-01
2021-12-31
0001164888
KBPH:GreenSunMedicalLLCMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:ClassAOnePreferredOwnershipUnitsThreeMember
2021-04-01
2021-12-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneOneMember
2020-04-01
2021-03-31
0001164888
KBPH:AcheliosTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemeberTwoThousandTwentyOneTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:AvisiTechnologiesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueJulyTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:BasepawsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteOnePercentageDueAprilTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:BeamSemiConductorIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueMarchTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:CorinnovaIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyFourMember
2020-04-01
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueSeptemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:CyberdonticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueFebruaryTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:DeepBlueMedicalAdvancesIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueJuneTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:EveryKeyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:IdenticalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwoPercentageDueMayTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueOctoberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueJulyTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueFebruaryTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:INBayTechnonlogyIncMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteTwelvePercentageDueDecemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:KianaAnalyticsMember
KBPH:TechnologyMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteThreePercentageDueDecemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:KiotechMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueNovemberTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyMember
2020-04-01
2021-03-31
0001164888
KBPH:LifewaveBiomedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyOnlyMember
2020-04-01
2021-03-31
0001164888
KBPH:NavauxIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:NeuroFoutyTwoIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:OctagonTherapeuticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteFivePercentageDueJuneTwoThousandTwentyOneOnlyMember
2020-04-01
2021-03-31
0001164888
KBPH:PerikineticsIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSixPercentageDueMayTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:PreviewMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteSevenPercentageDueJanuaryTwoThousandTwentyThreeMember
2020-04-01
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueAprilTwoThousandTwentyOnePlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:SageMedicCorpMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDueDecemberTwoThousandTwentyTwoPlusWarrantsMember
2020-04-01
2021-03-31
0001164888
KBPH:ValfixMedicalIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageDecemberTwoThousandTwentyOneMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:CorporateNoteSecuritiesMember
KBPH:ConvertibleNoteEightPercentageMarchTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoMember
2020-04-01
2021-03-31
0001164888
KBPH:XpanIncMember
KBPH:LifeScienceMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:ConvertibleNoteEightPercentageJuneTwoThousandTwentyTwoOnlyMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:AltisBiosystemsMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:AstrocytePharmaceuticalsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
KBPH:CnoteGroupIncMember
2020-04-01
2021-03-31
0001164888
KBPH:FintechMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedThreePreferredMember
KBPH:CnoteGroupIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:ColabsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:ConnectusServicesLtdMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:DeepBlueMedicalAdvancesIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:EumentisThereapeuticsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:FemtoDXIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
KBPH:ILumenScientificIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsOneMember
KBPH:ILumenScientificIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:InhalonBiopharmaIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:LightLineMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
KBPH:LightLineMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:LightLineMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredPlusWarrantsMember
KBPH:LightLineMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesAPreferredStockMember
KBPH:LowellTherapeuticsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredStockOneMember
KBPH:LowellTherapeuticsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredPlusWarrantsMember
KBPH:MicronicTechnologiesIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedTwoPreferredMember
KBPH:NeuroflowIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
us-gaap:SeriesBPreferredStockMember
KBPH:NeuroflowIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:NewViewSurgicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredPlusWarrantsMember
KBPH:OtomagneticsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:PromaxoIncMember
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBOnePreferredConvertedNoteMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:SealRockTherapeuticsIncMember
2020-04-01
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredMember
KBPH:ShyftFKACraterGroupIncMember
2020-04-01
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAPreferredConvertedNoteMember
KBPH:ShyftFKACraterGroupIncMember
2020-04-01
2021-03-31
0001164888
KBPH:TechnologyMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesAOnePreferredConvertedNoteMember
KBPH:ShyftFKACraterGroupIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsMember
KBPH:TrellisBioscienceLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsOneMember
KBPH:TrellisBioscienceLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesBPreferredPlusWarrantsTwoMember
KBPH:TrellisBioscienceLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredMember
KBPH:ValfixMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedOnePreferredConvertedNoteMember
KBPH:VisgenxIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteMember
KBPH:VisgenxIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:PreferredInvestmentsMember
KBPH:SeriesSeedPreferredConvertedNoteOneMember
KBPH:VisgenxIncMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
KBPH:BendaRXCorpMember
2020-04-01
2021-03-31
0001164888
KBPH:LifeScienceMember
KBPH:CommonStockInvestmentsMember
KBPH:CommonStockOneMember
KBPH:BendaRXCorpMember
2020-04-01
2021-03-31
0001164888
KBPH:BoardwalkTechMember
KBPH:TechnologyMember
KBPH:CommonStockInvestmentsMember
us-gaap:CommonStockMember
2020-04-01
2021-03-31
0001164888
KBPH:SeriesAOneOwnershipUnitsMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:EnduralockLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:SeriesAOneOwnershipUnitsOneMember
KBPH:TechnologyMember
KBPH:OtherInvestmentMember
KBPH:EnduralockLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsOneMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2020-04-01
2021-03-31
0001164888
KBPH:ClassAOnePreferredOwnershipUnitsTwoMember
KBPH:LifeScienceMember
KBPH:OtherInvestmentMember
KBPH:GreenSunMedicalLLCMember
2020-04-01
2021-03-31
0001164888
2018-03-31
0001164888
srt:MaximumMember
2021-12-31
0001164888
srt:ChiefExecutiveOfficerMember
2021-01-01
2021-01-02
0001164888
srt:ChiefExecutiveOfficerMember
2021-10-01
2021-12-31
0001164888
srt:ChiefExecutiveOfficerMember
2021-04-01
2021-12-31
0001164888
srt:ChiefExecutiveOfficerMember
2021-12-31
0001164888
srt:ChiefExecutiveOfficerMember
2020-10-01
2020-12-31
0001164888
srt:ChiefExecutiveOfficerMember
2020-04-01
2020-12-31
0001164888
srt:RestatementAdjustmentMember
2021-07-01
2021-09-30
0001164888
srt:RestatementAdjustmentMember
2021-04-01
2021-09-30
0001164888
srt:RestatementAdjustmentMember
2021-04-01
2021-06-30
0001164888
KBPH:ConsultantsAndAdvisorsMember
2021-10-01
2021-12-31
0001164888
KBPH:ConsultantsAndAdvisorsMember
2020-10-01
2020-12-31
0001164888
KBPH:ConsultantsAndAdvisorsMember
2021-04-01
2021-12-31
0001164888
KBPH:ConsultantsAndAdvisorsMember
2020-04-01
2020-12-31
0001164888
srt:ScenarioPreviouslyReportedMember
2021-07-01
2021-09-30
0001164888
srt:ScenarioPreviouslyReportedMember
2021-04-01
2021-06-30
0001164888
srt:ScenarioPreviouslyReportedMember
2021-04-01
2021-09-30
0001164888
2021-07-01
2021-09-30
0001164888
2021-04-01
2021-06-30
0001164888
2021-04-01
2021-09-30
0001164888
us-gaap:CommonStockMember
2021-10-01
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-10-01
2021-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2021-10-01
2021-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:EmployeeStockOptionMember
2021-10-01
2021-12-31
0001164888
us-gaap:EmployeeStockOptionMember
2021-04-01
2021-12-31
0001164888
us-gaap:WarrantMember
2021-10-01
2021-12-31
0001164888
us-gaap:WarrantMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2020-10-01
2020-12-31
0001164888
us-gaap:SeriesBPreferredStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:EmployeeStockOptionMember
2020-10-01
2020-12-31
0001164888
us-gaap:EmployeeStockOptionMember
2020-04-01
2020-12-31
0001164888
us-gaap:WarrantMember
2020-10-01
2020-12-31
0001164888
us-gaap:WarrantMember
2020-04-01
2020-12-31
0001164888
KBPH:ConvertibleNotesMember
2021-12-31
0001164888
KBPH:ConvertibleNotesMember
2021-03-31
0001164888
KBPH:PreferredStockFairValueMember
2021-12-31
0001164888
KBPH:PreferredStockFairValueMember
2021-03-31
0001164888
us-gaap:PreferredStockMember
2021-03-31
0001164888
us-gaap:CommonStockMember
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-03-31
0001164888
KBPH:SafeMember
2021-12-31
0001164888
KBPH:SafeMember
2021-03-31
0001164888
KBPH:OtherOwnershipUnitsMember
2021-12-31
0001164888
KBPH:OtherOwnershipUnitsMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:BasepawsIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:CyberdonticsIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:PromaxoIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:PromaxoIncMember
2021-04-01
2021-12-31
0001164888
srt:WeightedAverageMember
KBPH:PromaxoIncMember
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-04-01
2021-12-31
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-12-31
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
KBPH:ConvertibleDebtSecuritiesOtherMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:InhalonIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:InhalonIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ValfixIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ValfixIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ShyftMovingIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:ShyftMovingIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:SealRockTherapeuticsIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:SealRockTherapeuticsIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-04-01
2021-12-31
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-12-31
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:PromaxoIncMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-04-01
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
2021-12-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KitotechMedicalIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
KBPH:KitotechMedicalIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2020-04-01
2021-03-31
0001164888
srt:MinimumMember
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
srt:MaximumMember
KBPH:InvestmentFairValueMember
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:FemtoDXIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesMember
KBPH:NeuroflowIncMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:PreferredStockInPrivateCompaniesOtherMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:CommonStockInPrivateCompaniesMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
KBPH:SafeMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
us-gaap:OtherInvestmentsMember
2020-04-01
2021-03-31
0001164888
KBPH:InvestmentFairValueMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-12-31
0001164888
KBPH:PreferredStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPrivateCompaniesMember
2021-12-31
0001164888
KBPH:CommonStockInPrivateCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:SafeMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:SafeMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:SafeMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PrivatePortfolioCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PrivatePortfolioCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PrivatePortfolioCompaniesMember
2021-12-31
0001164888
KBPH:PrivatePortfolioCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPublicCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPublicCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPublicCompaniesMember
2021-12-31
0001164888
KBPH:CommonStockInPublicCompaniesMember
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
2021-12-31
0001164888
us-gaap:FairValueInputsLevel2Member
2021-12-31
0001164888
us-gaap:FairValueInputsLevel3Member
2021-12-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:ConvertibleDebtSecuritiesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PreferredStockInPrivateCompaniesMember
2021-03-31
0001164888
KBPH:PreferredStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
KBPH:CommonStockInPrivateCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:SafeMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:OtherInvestmentsMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
KBPH:PrivatePortfolioCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
KBPH:CommonStockInPublicCompaniesMember
2021-03-31
0001164888
us-gaap:FairValueInputsLevel1Member
2021-03-31
0001164888
us-gaap:FairValueInputsLevel2Member
2021-03-31
0001164888
us-gaap:FairValueInputsLevel3Member
2021-03-31
0001164888
country:US
2021-04-01
2021-12-31
0001164888
country:CA
2021-04-01
2021-12-31
0001164888
KBPH:RestOfWorldMember
2021-04-01
2021-12-31
0001164888
country:US
2020-03-31
0001164888
country:CA
2020-03-31
0001164888
KBPH:RestOfWorldMember
2020-03-31
0001164888
country:US
2020-04-01
2020-12-31
0001164888
country:CA
2020-04-01
2020-12-31
0001164888
KBPH:RestOfWorldMember
2020-04-01
2020-12-31
0001164888
country:US
2020-12-31
0001164888
country:CA
2020-12-31
0001164888
KBPH:RestOfWorldMember
2020-12-31
0001164888
KBPH:FintechMember
2021-03-31
0001164888
KBPH:TechnologyMember
2021-03-31
0001164888
KBPH:LifeScienceMember
2021-03-31
0001164888
KBPH:FintechMember
2021-04-01
2021-12-31
0001164888
KBPH:TechnologyMember
2021-04-01
2021-12-31
0001164888
KBPH:LifeScienceMember
2021-04-01
2021-12-31
0001164888
KBPH:FintechMember
2021-12-31
0001164888
KBPH:TechnologyMember
2021-12-31
0001164888
KBPH:LifeScienceMember
2021-12-31
0001164888
KBPH:FintechMember
2020-03-31
0001164888
KBPH:TechnologyMember
2020-03-31
0001164888
KBPH:LifeScienceMember
2020-03-31
0001164888
KBPH:FintechMember
2020-04-01
2020-12-31
0001164888
KBPH:TechnologyMember
2020-04-01
2020-12-31
0001164888
KBPH:LifeScienceMember
2020-04-01
2020-12-31
0001164888
KBPH:FintechMember
2020-12-31
0001164888
KBPH:TechnologyMember
2020-12-31
0001164888
KBPH:LifeScienceMember
2020-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2021-04-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
2021-04-01
2021-12-31
0001164888
KBPH:SafeMember
2021-04-01
2021-12-31
0001164888
KBPH:OtherOwnershipUnitsMember
2021-04-01
2021-12-31
0001164888
us-gaap:PreferredStockMember
2021-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-03-31
0001164888
us-gaap:PreferredStockMember
2020-03-31
0001164888
us-gaap:CommonStockMember
2020-03-31
0001164888
KBPH:SafeMember
2020-03-31
0001164888
KBPH:OtherOwnershipUnitsMember
2020-03-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-04-01
2020-12-31
0001164888
us-gaap:PreferredStockMember
2020-04-01
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-04-01
2020-12-31
0001164888
KBPH:SafeMember
2020-04-01
2020-12-31
0001164888
KBPH:OtherOwnershipUnitsMember
2020-04-01
2020-12-31
0001164888
us-gaap:ConvertibleDebtSecuritiesMember
2020-12-31
0001164888
us-gaap:PreferredStockMember
2020-12-31
0001164888
us-gaap:CommonStockMember
2020-12-31
0001164888
KBPH:SafeMember
2020-12-31
0001164888
KBPH:OtherOwnershipUnitsMember
2020-12-31
0001164888
us-gaap:SeriesAPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-03-02
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-02-28
2021-03-02
0001164888
KBPH:SeriesAOneAndSeriesATwoPreferredStockMember
us-gaap:IPOMember
2021-04-01
2021-12-31
0001164888
KBPH:SeriesAOnePreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:SeriesATwoPreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
us-gaap:SeriesBPreferredStockMember
2021-03-02
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-02-28
2021-03-02
0001164888
KBPH:SeriesBOneAndSeriesBTwoPreferredStockMember
us-gaap:IPOMember
2021-02-28
2021-03-02
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:SeriesBTwoPreferredStockMember
2021-04-01
2021-12-31
0001164888
KBPH:SeriesBOnePreferredStockMember
2021-10-01
2021-12-31
0001164888
KBPH:SeriesBThreePreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-10-01
2021-12-31
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-04-01
2021-12-31
0001164888
us-gaap:CommonStockMember
KBPH:AmendmentofPreferredStockMember
2021-03-31
0001164888
KBPH:TwoThousandAndEighteenStockOptionAndIncentivePlanMember
2018-04-01
2018-04-30
0001164888
KBPH:TwoThousandNineteenStockOptionAndIncentivePlanMember
2019-07-31
0001164888
KBPH:TwoThousandAndTwentyStockOptionAndIncentivePlanMember
2020-12-31
0001164888
KBPH:TwoThousandAndTwentyOneStockOptionAndIncentivePlanMember
2021-12-20
0001164888
KBPH:NonQualifiedStockOptionsMember
2021-10-01
2021-12-31
0001164888
KBPH:NonQualifiedStockOptionsMember
2020-10-01
2020-12-31
0001164888
KBPH:NonQualifiedStockOptionsMember
2021-04-01
2021-12-31
0001164888
KBPH:NonQualifiedStockOptionsMember
2020-04-01
2020-12-31
0001164888
us-gaap:WarrantMember
2021-04-01
2021-12-31
0001164888
srt:MinimumMember
2021-03-31
0001164888
srt:MaximumMember
2021-03-31
0001164888
srt:MinimumMember
2021-04-01
2021-12-31
0001164888
srt:MaximumMember
2021-04-01
2021-12-31
0001164888
srt:MinimumMember
2020-04-01
2021-03-31
0001164888
srt:MaximumMember
2020-04-01
2021-03-31
0001164888
2020-04-01
2021-03-31
0001164888
us-gaap:WarrantMember
2021-12-31
0001164888
us-gaap:WarrantMember
2020-03-31
0001164888
us-gaap:WarrantMember
2020-04-01
2020-12-31
0001164888
us-gaap:WarrantMember
2020-12-31
0001164888
us-gaap:WarrantMember
2019-04-01
2020-03-31
0001164888
us-gaap:WarrantMember
2021-03-31
0001164888
us-gaap:WarrantMember
2020-04-01
2021-03-31
0001164888
us-gaap:SubsequentEventMember
2022-01-01
2022-02-22
0001164888
us-gaap:SubsequentEventMember
2022-02-22
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
KBPH:Integer
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
For
the quarterly period ended December 31, 2021
or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE
ACT OF 1934
For
the transition period from: _____________ to _____________
KYTO
TECHNOLOGY AND LIFE SCIENCE, INC.
(Exact
name of registrant as specified in its charter)
delaware
|
|
000-50390
|
|
65-1086538
|
(State
or Other Jurisdiction |
|
(Commission
|
|
(I.R.S.
Employer |
of
Incorporation) |
|
File
Number) |
|
Identification
No.) |
13050
Paloma Road, Los Altos Hills, CA 94022
(Address
of Principal Executive Office) (Zip Code)
(650)
204 7896
(Registrant’s
telephone number, including area code)
(Former
name, former address and former fiscal year, if changed since last report)
Title
of each class |
|
Trading
Symbol |
|
Exchange |
Common
stock |
|
KBPH |
|
OTC
QB |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (ss. 232.405 of this chapter) during the preceding 12 (or for such shorter period that the registrant was required
to submit such files). ☒ Yes ☐ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
|
Non-accelerated
filer |
☐ |
Smaller
reporting company |
☒ |
|
Emerging
growth company |
☐ |
|
|
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Yes ☒ No
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes ☒ No
Indicate
the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
13,287,621
Common Shares - $0.01 Par Value - as of February 18,
2022
Kyto
Technology and Life Science, Inc.
For
the quarterly period ended December 31, 2021
INDEX
PART
I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
Kyto
Technology and Life Science, Inc.
Condensed
Statement of Assets and Liabilities
| |
December 31, | | |
March 31, | |
| |
2021 | | |
2021 | |
| |
(Unaudited) | | |
| |
ASSETS | |
| | | |
| | |
Investments at fair value (cost of $8,926,469 and $5,686,545, respectively) | |
$ | 12,156,511 | | |
$ | 6,821,407 | |
Cash | |
| 608,223 | | |
| 1,437,868 | |
Other assets | |
| 293,564 | | |
| 169,891 | |
Total Assets | |
$ | 13,058,298 | | |
$ | 8,429,166 | |
| |
| | | |
| | |
LIABILITIES | |
| | | |
| | |
| |
| | | |
| | |
Liabilities | |
| | | |
| | |
Accounts payable and accrued liabilities | |
$ | 63,675 | | |
$ | 193,141 | |
Accrued liabilities - related parties | |
| 83,000 | | |
| 51,420 | |
Common stock subscription liability | |
| - | | |
| 1,191,442 | |
Total Liabilities | |
| 146,675 | | |
| 1,436,003 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 3) | |
| - | | |
| - | |
| |
| | | |
| | |
Net Assets | |
| | | |
| | |
Preferred stock authorized but not designated, $0.01
par value 16,800,000
shares, none issued or outstanding
as of December 31, 2021 and March 31, 2021, respectively | |
| - | | |
| - | |
Class A (including Class A-1 and A-2) preferred convertible stock, $0.01 par value, 4,200,000 shares
designated, 4,200,000 issued and outstanding as of December 31, 2021 and March 31, 2021, respectively; aggregate liquidation
preference of $6,720,000 at December 31, 2021 and March 31, 2021, respectively | |
| 42,001 | | |
| 42,001 | |
Class B (including Class B-1, B-2 and B-3) preferred convertible stock, $0.01
par value, 9,000,000
shares designated, 8,087,656
and 3,628,906
issued and outstanding as of December 31, 2021 and March 31, 2021, respectively, aggregate liquidation preference of $6,951,945
at December 31, 2021 and $2,903,125
at March 31, 2021, respectively | |
| 80,877 | | |
| 36,289 | |
Preferred stock, value | |
| | | |
| | |
Common stock, $0.01 par value, 40,000,000 shares authorized, 13,287,621 and
9,983,082 issued and outstanding as of December 31, 2021 and March 31 2021, respectively | |
| 132,876 | | |
| 99,831 | |
Additional paid-in capital | |
| 44,630,564 | | |
| 39,772,228 | |
Accumulated deficit | |
| (31,974,695 | ) | |
| (32,957,186 | ) |
| |
| | | |
| | |
Total Net Assets | |
| 12,911,623 | | |
| 6,993,163 | |
| |
| | | |
| | |
Total Liabilities and Net Assets | |
$ | 13,058,298 | | |
$ | 8,429,166 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statement of Operations
(Unaudited)
| |
2021 | | |
2020 | | |
2021 | | |
2020 | |
| |
For the Three months ended December 31, | | |
For the Nine months ended December 31, | |
| |
2021 | | |
2020 | | |
2021 | | |
2020 | |
| |
| | |
| | |
| | |
| |
INVESTMENT INCOME | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Interest and other income | |
$ | - | | |
$ | 5 | | |
$ | - | | |
$ | 505 | |
| |
| | | |
| | | |
| | | |
| | |
Total investment income | |
| - | | |
| 5 | | |
| - | | |
| 505 | |
| |
| | | |
| | | |
| | | |
| | |
EXPENSES | |
| | | |
| | | |
| | | |
| | |
Professional fees | |
| 98,241 | | |
| 91,669 | | |
| 371,600 | | |
| 168,212 | |
Other operating expenses | |
| 273,473 | | |
| 241,047 | | |
| 741,089 | | |
| 363,983 | |
Total expenses | |
| 371,714 | | |
| 332,716 | | |
| 1,112,689 | | |
| 532,195 | |
| |
| | | |
| | | |
| | | |
| | |
Net investment loss | |
| (371,714 | ) | |
| (332,711 | ) | |
| (1,112,689 | ) | |
| (531,690 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net change in unrealized gain on investments | |
| 691,864 | | |
| 328,694 | | |
| 2,095,180 | | |
| 806,942 | |
| |
| | | |
| | | |
| | | |
| | |
Net increase (decrease) in net assets resulting from operations | |
| 320,150 | | |
| (4,017 | ) | |
| 982,491 | | |
| 275,252 | |
| |
| | | |
| | | |
| | | |
| | |
Less: dividends attributable to Class B-1, B-2 and B-3 | |
| (131,999 ) | | |
| - | | |
| (482,693) | | |
| - | |
Less: dividends attributable to Class B-1, B-2 and B-3
Preferred Stock (see Note 2 (I)) | |
| (131,999 | ) | |
| - | | |
| (482,693 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net increase (decrease) in net assets resulting from
operations attributable to Common Shareholders | |
$ | 188,151 | | |
$ | (4,017 | ) | |
$ | 499,798 | | |
$ | 275,252 | |
| |
| | | |
| | | |
| | | |
| | |
Basic earnings per Common Share, | |
| | | |
| | | |
| | | |
| | |
Net increase in net assets resulting from operations per common share | |
$ | 0.01 | | |
$ | - | | |
$ | 0.04 | | |
$ | 0.04 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding | |
| 13,287,621 | | |
| 8,528,007 | | |
| 13,273,038 | | |
| 6,737,152 | |
| |
| | | |
| | | |
| | | |
| | |
Fully-diluted earnings per Common Share, | |
| | | |
| | | |
| | | |
| | |
Net increase in net assets resulting from operations per common share | |
$ | 0.01 | | |
$ | - | | |
$ | 0.02 | | |
$ | 0.02 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding | |
| 23,516,038 | | |
| 19,272,128 | | |
| 22,400,260 | | |
| 17,142,683 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statement of Changes in Net Assets for the Three and Nine months ended December 31, 2021
(Unaudited)
| |
Preferred
A
(Including
Class A-1,
A-2) | | |
Preferred
A
Stock
(Including
Class A-1,
A-2) | | |
Preferred
B
(Including
Class B-1,
B-2, B-3) | | |
Preferred
B
Stock
(Including
Class B-1,
B-2, B-3) | | |
Common | | |
Common
Stock | | |
Additional
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
Three months ended December
31, 2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, September
30, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 5,911,406 | | |
$ | 59,114 | | |
| 13,287,621 | | |
$ | 132,876 | | |
$ | 42,878,748 | | |
$ | (32,294,845 | ) | |
$ | 10,817,894 | |
Net increase in net assets
resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 320,150 | | |
| 320,150 | |
Sale of Class B-3 Preferred
stock at $0.80 per share | |
| - | | |
| - | | |
| 2,176,250 | | |
| 21,763 | | |
| - | | |
| - | | |
| 1,719,237 | | |
| - | | |
| 1,741,000 | |
Sale of Common stock | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Sale of common stock $0.40 per share, shares | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Exercise of stock options | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Exercise of stock options,
shares | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for warrants
and options exercise | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Common stock issued for warrants
and options exercise, shares | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Compensation
expense from stock options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 32,579 | | |
| - | | |
| 32,579 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
December 31, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 8,087,656 | | |
$ | 80,877 | | |
| 13,287,621 | | |
$ | 132,876 | | |
$ | 44,630,564 | | |
$ | (31,974,695 | ) | |
$ | 12,911,623 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Nine months ended December
31, 2021 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, March 31, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 3,628,906 | | |
$ | 36,289 | | |
| 9,983,082 | | |
$ | 99,831 | | |
$ | 39,772,228 | | |
$ | (32,957,186 | ) | |
$ | 6,993,163 | |
Net increase in net assets
resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 982,491 | | |
| 982,491 | |
Sale of Class B-1 and B-3 Preferred
stock at $0.80 per share | |
| - | | |
| - | | |
| 4,458,750 | | |
| 44,588 | | |
| - | | |
| - | | |
| 3,522,413 | | |
| - | | |
| 3,567,001 | |
Sale of Common stock at $0.40 per share | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,285,789 | | |
| 32,858 | | |
| 1,281,459 | | |
| - | | |
| 1,314,317 | |
Exercise of stock options | |
| - | | |
| - | | |
| - | | |
| - | | |
| 18,750 | | |
| 187 | | |
| 431 | | |
| - | | |
| 618 | |
Compensation
expense from stock options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 54,033 | | |
| - | | |
| 54,033 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
December 31, 2021 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 8,087,656 | | |
$ | 80,877 | | |
| 13,287,621 | | |
$ | 132,876 | | |
$ | 44,630,564 | | |
$ | (31,974,695 | ) | |
$ | 12,911,623 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statement of Changes in Net Assets for the Three and Nine months ended December 31, 2020
(Unaudited)
| |
Preferred
A | | |
Preferred
A
Shares | | |
Preferred
B | | |
Preferred
B
Shares | | |
Common | | |
Common
Stock | | |
Additional
Paid-in | | |
Accumulated | | |
| |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Three months ended December
31, 2020 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, September
30, 2020 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 2,337,500 | | |
$ | 23,375 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 37,211,970 | | |
$ | (33,104,983 | ) | |
$ | 4,230,731 | |
Net decrease in net assets
resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (4,017 | ) | |
| (4,017 | ) |
Sale of Class B Preferred stock
at $0.80 per share | |
| - | | |
| - | | |
| 753,906 | | |
| 7,539 | | |
| - | | |
| - | | |
| 595,586 | | |
| - | | |
| 603,125 | |
Common stock issued for warrants
and options exercise | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,965,000 | | |
| 39,650 | | |
| 1,526,580 | | |
| - | | |
| 1,566,230 | |
Compensation
expense from stock options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,474 | | |
| - | | |
| 3,474 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
December 31, 2020 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 3,091,406 | | |
$ | 30,914 | | |
| 9,801,832 | | |
$ | 98,018 | | |
$ | 39,337,610 | | |
$ | (33,109,000 | ) | |
$ | 6,399,543 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Nine months ended December
31, 2020 | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance, March 31, 2020 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 812,500 | | |
$ | 8,125 | | |
| 5,836,832 | | |
$ | 58,368 | | |
$ | 35,943,369 | | |
$ | (33,384,252 | ) | |
$ | 2,667,611 | |
Net increase in net assets
resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 275,252 | | |
| 275,252 | |
Net increase (decrease) in net assets resulting from operations | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 275,252 | | |
| 275,252 | |
Sale of Class B Preferred stock
at $0.80 per share | |
| - | | |
| - | | |
| 2,278,906 | | |
| 22,789 | | |
| - | | |
| - | | |
| 1,850,336 | | |
| - | | |
| 1,873,125 | |
Sale of Class B, B-1 and B-3 Preferred stock | |
| - | | |
| - | | |
| 2,278,906 | | |
| 22,789 | | |
| - | | |
| - | | |
| 1,850,336 | | |
| - | | |
| 1,873,125 | |
Common stock issued for warrants
and options exercise | |
| - | | |
| - | | |
| - | | |
| - | | |
| 3,965,000 | | |
| 39,650 | | |
| 1,526,579 | | |
| - | | |
| 1,566,229 | |
Compensation
expense from stock options | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 17,326 | | |
| - | | |
| 17,326 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance,
December 31, 2020 | |
| 4,200,000 | | |
$ | 42,001 | | |
| 3,091,406 | | |
$ | 30,914 | | |
| 9,801,832 | | |
$ | 98,018 | | |
$ | 39,337,610 | | |
$ | (33,109,000 | ) | |
$ | 6,399,543 | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Condensed
Statement of Cash Flows
(Unaudited)
| |
2021 | | |
2020 | |
| |
Nine months months ended | |
| |
December 31, | |
| |
2021 | | |
2020 | |
| |
| | |
| |
Operating activities: | |
| | | |
| | |
Net increase in net assets resulting from operations | |
$ | 982,491 | | |
$ | 275,252 | |
Adjustments to reconcile net increase in net assets resulting from operations to
net cash used in operating activities | |
| | | |
| | |
Net change in unrealized gain on investments | |
| (2,095,180 | ) | |
| (806,942 | ) |
Stock option compensation expense | |
| 54,033 | | |
| 17,326 | |
Change in operating assets and liabilities | |
| | | |
| | |
Other assets | |
| (123,673 | ) | |
| 500 | |
Accounts payable and accrued liabilities | |
| (129,466 | ) | |
| 47,708 | |
Accrued liabilities to related parties | |
| 31,580 | | |
| - | |
Purchases of investments | |
| (3,328,478 | ) | |
| (2,410,000 | ) |
Proceeds from sale of investments | |
| 88,554 | | |
| - | |
Net cash used in operating activities | |
| (4,520,139 | ) | |
| (2,876,156 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Sale of Common stock in connection with preference rights (see Note 6) | |
| 122,875 | | |
| - | |
Sale of Common stock from exercise of warrants and stock options | |
| 618 | | |
| 1,566,229 | |
Sale of Class B-1 Preferred stock | |
| 1,626,000 | | |
| 1,873,125 | |
Sale of Class B-3 Preferred stock | |
| 1,941,001 | | |
| - | |
Deferred fundraising expenses | |
| - | | |
| (36,409 | ) |
Receipt of SBA loan | |
| - | | |
| 1,000 | |
Advances from related party | |
| - | | |
| 2,250 | |
Net cash provided by financing activities | |
| 3,690,494 | | |
| 3,406,195 | |
| |
| | | |
| | |
Net increase/(decrease) in cash | |
| (829,645 | ) | |
| 530,039 | |
| |
| | | |
| | |
Cash, beginning of period | |
| 1,437,868 | | |
| 33,756 | |
Cash, end of period | |
$ | 608,223 | | |
$ | 563,795 | |
| |
| | | |
| | |
Supplemental cash flow information | |
| | | |
| | |
Taxes paid | |
$ | 800 | | |
$ | 800 | |
Supplemental schedule of noncash financing activities: | |
| | | |
| | |
Conversion of common stock subscription liability to common stock | |
$ | 1,191,442 | | |
$ | - | |
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Schedule
of Investments as of December 31, 2021
(Unaudited)
|
|
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | |
|
Fair
value |
| |
%
of net assets (a) | |
Convertible
loan investments | |
| | |
|
| |
| |
| | |
|
|
Abfero Pharmaceuticals
Inc |
| |
Life science | |
Convertible Note,
6% due, December 2022 | |
$ | 11,447 | |
|
$ | 15,589 |
| |
| 0.1 | % |
( i ) |
|
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note, 8% due, December
2021 | |
| 100,000 | |
|
| 127,200 |
| |
| 1.0 | % |
( i ) |
|
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note, 8% due December
2021 | |
| 25,000 | |
|
| 30,540 |
| |
| 0.2 | % |
( i ) |
|
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note, 8% due December
2021 | |
| 50,000 | |
|
| 57,595 |
| |
| 0.4 | % |
( i ) |
|
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note Sidecar, 25%
discount. No interest | |
| 50,000 | |
|
| 50,000 |
| |
| 0.4 | % |
|
|
AOA DX Inc |
| |
Life science | |
Convertible Note, 4%, due May
2024 | |
| 100,000 | |
|
| 102,575 |
| |
| 0.8 | % |
|
|
Avisi Technologies Inc |
| |
Life science | |
Convertible Note, 8% due July
2022 | |
| 50,000 | |
|
| 55,688 |
| |
| 0.4 | % |
|
|
Basepaws Inc |
| |
Life science | |
Convertible Note, 1% due April
2020 | |
| 50,000 | |
|
| 244,980 |
| |
| 1.9 | % |
|
|
Basepaws Inc |
| |
Life science | |
Convertible Note, 6% due October
2023 | |
| 150,000 | |
|
| 150,000 |
| |
| 1.2 | % |
( i ) |
|
Beam Semiconductor Inc |
* | |
Technology | |
Convertible Note, 8% due April
2022 | |
| 150,000 | |
|
| 180,082 |
| |
| 1.4 | % |
( i ) |
|
Beam Semiconductor Inc |
* | |
Technology | |
Convertible Note, 8% due March
2021 | |
| 50,000 | |
|
| 57,299 |
| |
| 0.4 | % |
( i ) |
|
Beam Semiconductor Inc |
* | |
Technology | |
Convertible Note, 8% due March
2022 | |
| 100,000 | |
|
| 105,721 |
| |
| 0.8 | % |
|
|
CoLabs Inc |
| |
Life science | |
Convertible Note, 6% due February
2023 | |
| 50,000 | |
|
| 51,060 |
| |
| 0.4 | % |
|
|
Corinnova Inc |
| |
Life science | |
Convertible Note, 6% due December
2024 | |
| 100,000 | |
|
| 106,723 |
| |
| 0.8 | % |
|
|
Corinnova Inc |
| |
Life science | |
Convertible Note, 6% due December
2024 | |
| 50,000 | |
|
| 50,921 |
| |
| 0.4 | % |
* |
|
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 8% due September
2022 | |
| 30,000 | |
|
| 71,733 |
| |
| 0.6 | % |
* |
|
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 8% due February
2023 | |
| 35,000 | |
|
| 83,689 |
| |
| 0.6 | % |
* |
|
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 0% no due
date | |
| 35,000 | |
|
| 35,000 |
| |
| 0.3 | % |
|
|
Deep Blue Medical Advances
Inc |
| |
Life science | |
Convertible Note, 6% due June
2022 | |
| 50,000 | |
|
| 53,107 |
| |
| 0.4 | % |
|
|
Deep Blue Medical Advances
Inc |
| |
Life science | |
Convertible Note, 6% due June
2022 | |
| 50,000 | |
|
| 50,181 |
| |
| 0.4 | % |
|
|
Every Key Inc |
| |
Technology | |
Convertible Note, 5% due December
2023 | |
| 100,000 | |
|
| 110,288 |
| |
| 0.9 | % |
|
|
Femto DX Inc. |
| |
Life science | |
Convertible Note, 12% due December
2022 | |
| 100,000 | |
|
| 100,526 |
| |
| 0.8 | % |
|
|
Identical Inc |
| |
Life science | |
Convertible Note, 2% due May
2022 | |
| 100,000 | |
|
| 102,279 |
| |
| 0.8 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due October
2020 | |
| 50,000 | |
|
| 69,101 |
| |
| 0.5 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due July
2021 | |
| 30,000 | |
|
| 38,936 |
| |
| 0.3 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due February
2022 | |
| 50,000 | |
|
| 61,162 |
| |
| 0.5 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due December
2022 | |
| 40,000 | |
|
| 45,168 |
| |
| 0.3 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due December
2023 | |
| 50,000 | |
|
| 54,437 |
| |
| 0.4 | % |
( i )* |
|
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due December
2023 | |
| 25,000 | |
|
| 25,001 |
| |
| 0.2 | % |
* |
|
Iris R&D Group Inc |
* | |
Technology | |
Convertible Note, 8% May 2023 | |
| 50,000 | |
|
| 52,455 |
| |
| 0.4 | % |
|
|
Kiana Analytics Inc |
| |
Technology | |
Convertible Note, 3% December
2022 | |
| 100,000 | |
|
| 103,082 |
| |
| 0.8 | % |
|
|
Kitotech Medical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 100,000 | |
|
| 247,654 |
| |
| 1.9 | % |
|
|
Kitotech Medical Inc |
| |
Life science | |
Convertible Note, 6% due November
2022 | |
| 75,000 | |
|
| 87,030 |
| |
| 0.7 | % |
|
|
Lifewave Biomedical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 30,000 | |
|
| 34,187 |
| |
| 0.3 | % |
|
|
Lifewave Biomedical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 70,000 | |
|
| 77,974 |
| |
| 0.6 | % |
|
|
Lifewave Biomedical Inc |
| |
Life science | |
Convertible Note, 6% due December
2021 | |
| 50,000 | |
|
| 51,915 |
| |
| 0.4 | % |
|
|
Lowell Therapeutics Inc |
| |
Life science | |
Convertible Note, 8% no due
date | |
| 27,491 | |
|
| 28,509 |
| |
| 0.2 | % |
|
|
mmTron Inc |
| |
Technology | |
Convertible Note, 4% due April
2023 | |
| 100,000 | |
|
| 102,038 |
| |
| 0.8 | % |
|
|
Navaux Inc |
| |
Life science | |
Convertible Note, 6% due December
2023 | |
| 60,000 | |
|
| 63,748 |
| |
| 0.5 | % |
|
|
Neuro42 Inc. |
| |
Life science | |
Convertible Note, 8% due December
2023 | |
| 50,000 | |
|
| 53,573 |
| |
| 0.4 | % |
|
|
Neuro42 Inc. |
| |
Life science | |
Convertible Note, 5% due November
2023 | |
| 150,000 | |
|
| 150,801 |
| |
| 1.2 | % |
|
|
Octagon Therapeutics Inc |
| |
Life science | |
Convertible Note, 5% due June
2021 | |
| 50,000 | |
|
| 52,979 |
| |
| 0.4 | % |
|
|
Octagon Therapeutics Inc |
| |
Life science | |
Convertible Note, 5% due June
2021 | |
| 50,000 | |
|
| 52,849 |
| |
| 0.4 | % |
|
|
Perikinetics Inc |
| |
Life science | |
Convertible Note, 6% due May
2022 | |
| 100,000 | |
|
| 106,838 |
| |
| 0.8 | % |
|
|
Preview Medical Inc |
| |
Life science | |
Convertible Note, 7% due May
2022 | |
| 50,000 | |
|
| 50,278 |
| |
| 0.4 | % |
|
|
Preview Medical Inc |
| |
Life science | |
Convertible Note, 7% due January
2023 | |
| 100,000 | |
|
| 106,712 |
| |
| 0.8 | % |
|
|
Promaxo Inc |
| |
Life science | |
Convertible note, 5% due July
2022 | |
| 100,000 | |
|
| 185,136 |
| |
| 1.4 | % |
|
|
Rheos Inc |
| |
Life science | |
Convertible note, 8% due August
2026 | |
| 100,000 | |
|
| 103,090 |
| |
| 0.8 | % |
|
|
Saccharo Inc |
| |
Life science | |
Convertible note, 7% due September
2022 | |
| 50,000 | |
|
| 51,697 |
| |
| 0.4 | % |
|
|
SageMedic Corp |
| |
Life science | |
Convertible Note, 8% April
2021 plus warrants | |
| 50,000 | |
|
| 60,893 |
| |
| 0.5 | % |
|
|
SageMedic Corp |
| |
Life science | |
Convertible Note, 8% December
2022 plus warrants | |
| 75,000 | |
|
| 81,460 |
| |
| 0.6 | % |
|
|
Seal Rock Therapeutics Inc |
| |
Life science | |
Convertible Note , 6% due June
2023 | |
| 100,000 | |
|
| 100,000 |
| |
| 0.8 | % |
|
|
Sensing Electromagnetic Plus
Corp |
| |
Technology | |
Convertible Note, Fully reserved | |
| 50,000 | |
|
| 1 |
| |
| 0.0 | % |
|
|
Sensing Electromagnetic Plus
Corp |
| |
Technology | |
Convertible Note, Fully reserved | |
| 11,048 | |
|
| 1 |
| |
| 0.0 | % |
|
|
Shyft (FKA Crater Group Inc) |
| |
Technology | |
Convertible Note, 6% due April
2023 | |
| 100,000 | |
|
| 100,000 |
| |
| 0.8 | % |
|
|
Single Pass Inc |
| |
Life science | |
Convertible Note, 6% April
2024 | |
| 50,000 | |
|
| 51,726 |
| |
| 0.4 | % |
* |
|
Valfix Medical Inc |
* | |
Life science | |
Convertible Note, 8% December
2021 | |
| 50,000 | |
|
| 123,160 |
| |
| 1.0 | % |
* |
|
Xpan Inc |
* | |
Life science | |
Convertible Note, 8% due March
2022 | |
| 50,000 | |
|
| 57,310 |
| |
| 0.4 | % |
* |
|
Xpan Inc |
* | |
Life science | |
Convertible Note, 8% due June
2022 | |
| 25,000 | |
|
| 28,052 |
| |
| 0.2 | % |
* |
|
Xpan
Inc |
* | |
Life
science | |
Convertible Note, 8% due June
2022 | |
| 25,000 | |
|
| 28,047 |
| |
| 0.2 | % |
Total
Convertible loan investments | |
$ | 3,879,986 | |
|
$ | 4,679,776 |
| |
| 36.2 | % |
|
|
United States |
| |
| |
| |
$ | 3,034,986 | |
|
$ | 3,563,423 |
| |
| 27.6 | % |
|
|
Canada |
| |
| |
| |
| 495,000 | |
|
| 650,091 |
| |
| 5.0 | % |
|
|
Rest of World |
| |
| |
| |
| 350,000 | |
|
| 466,262 |
| |
| 3.6 | % |
Total
Convertible loan investments | |
$ | 3,879,986 | |
|
$ | 4,679,776 |
| |
| 36.2 | % |
Continued
to next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Schedule
of Investments as of December 31, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
|
%
of net assets (a) |
|
Preferred
stock investments | | |
| |
| |
| | | |
| | |
|
|
|
|
| |
Altis Biosystems |
| |
Life science | |
22,028 shares of Series Seed Preferred | |
$ | 50,000 | | |
$ | 50,000 | | |
|
0.4 |
% |
| |
Astrocyte Pharmaceuticals Inc |
| |
Life science | |
260,756 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
84,655 shares of series Seed-2
Preferred (converted SAFE) | |
| 51,500 | | |
| 59,783 | | |
|
0.5 |
% |
| |
Cnote Group, Inc |
| |
Fintech | |
93,807 shares of Series Seed-3
Preferred (converted note) | |
| 50,000 | | |
| 66,247 | | |
|
0.5 |
% |
| |
Colabs Inc |
| |
Life science | |
147,058 shares of Series A-1 Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
* | |
Connectus Services Ltd |
* | |
Technology | |
31,348 shares of Series Seed Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Deep Blue Medical Advances
Inc |
| |
Life science | |
10,474 shares of Series A Preferred | |
| 49,996 | | |
| 49,997 | | |
|
0.4 |
% |
| |
Distasense Inc (FKA Life Detection
Technologies Inc |
| |
Life science | |
117,813 shares of Series C Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Eumentis Thereapeutics Inc |
| |
Life science | |
85,009 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
FemtoDX Inc |
| |
Life science | |
42,436 shares of Series A Preferred | |
| 100,000 | | |
| 290,046 | | |
|
2.2 |
% |
| |
Healionics Corporation |
| |
Life science | |
35,075 of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Inhalon Biopharma Inc |
| |
Life science | |
18,843 shares of Series Seed Preferred | |
| 99,997 | | |
| 256,198 | | |
|
2.0 |
% |
| |
Kitotech Medical Inc |
| |
Life science | |
49,027shares of Series B Preferred | |
| 74,998 | | |
| 74,998 | | |
|
0.6 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
62,849 shares of Series Seed
Preferred (converted note) | |
| 30,000 | | |
| 38,031 | | |
|
0.3 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
141,871 shares of Series Seed
Preferred (converted note) | |
| 70,000 | | |
| 106,049 | | |
|
0.8 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
40,323 shares of Series Seed preferred | |
| 25,000 | | |
| 25,000 | | |
|
0.2 |
% |
| |
Light Line Medical Inc |
| |
Life science | |
72,464 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Lowell Therapeutics Inc |
| |
Life science | |
25,000 shares of Series B Preferred | |
| 100,000 | | |
| 100,001 | | |
|
0.8 |
% |
| |
Makani Science Inc |
| |
Life science | |
172,413 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Micronic Technologies Inc |
| |
Technology | |
51,929 shares of Series Seed-1
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Nanochon Inc |
| |
Life science | |
200,401 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Neuroflow Inc |
| |
Life science | |
98,684 shares of Series Seed -2 Preferred | |
| 150,000 | | |
| 540,053 | | |
|
4.2 |
% |
| |
Neuroflow Inc |
| |
Life science | |
20,429 shares of Series B Preferred | |
| 100,000 | | |
| 136,829 | | |
|
1.1 |
% |
| |
New View Surgical, Inc. |
| |
Life science | |
53,825 shares of Series A-1 Preferred | |
| 75,000 | | |
| 75,000 | | |
|
0.6 |
% |
| |
New View Surgical, Inc. |
| |
Life science | |
58,220 shares of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
* | |
Orion Biotechnology Inc |
* | |
Life science | |
5,824 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Otomagnetics Inc |
| |
Life science | |
16,538 shares of Series A-1 Preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Partheous Inc |
| |
Life science | |
50,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
| |
Promaxo |
| |
Life science | |
104,248 shares of Series B-1
Preferred, (converted note) | |
| 250,000 | | |
| 1,034,684 | | |
|
8.0 |
% |
| |
SageMedic Corp |
| |
Life science | |
12,717 shares of Series A Preferred | |
| 10,389 | | |
| 10,389 | | |
|
0.1 |
% |
| |
Seal Rock Therapeutics, Inc. |
| |
Life science | |
68,075 shares of Series Seed
Preferred, (converted note) | |
| 78,000 | | |
| 199,375 | | |
|
1.5 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
42,657 shares of Series A-1
Preferred (converted note) | |
| 51,500 | | |
| 107,059 | | |
|
0.8 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
28,147 shares of Series A Preferred
(converted note) | |
| 50,000 | | |
| 91,771 | | |
|
0.7 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
21,774 shares of Series A-1
Preferred plus warrants | |
| 50,000 | | |
| 70,990 | | |
|
0.5 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
100,000 shares of Series B
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Trio Labs Inc |
| |
Life science | |
29,809 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.4 |
% |
* | |
Valfix Medical Inc |
* | |
Life science | |
27,217 shares of Series Seed Preferred | |
| 50,000 | | |
| 105,607 | | |
|
0.8 |
% |
| |
Vesteck Inc |
| |
Life science | |
34,783 shares of Series A preferred | |
| 100,000 | | |
| 100,000 | | |
|
0.8 |
% |
| |
Visgenx Inc |
| |
Life science | |
7,833 shares of Series Seed-1
Preferred (converted note) | |
| 30,000 | | |
| 46,352 | | |
|
0.4 |
% |
| |
Visgenx Inc |
| |
Life science | |
4,132 shares of Series Seed
Preferred (converted note) | |
| 25,000 | | |
| 25,648 | | |
|
0.2 |
% |
| |
Visgenx
Inc |
| |
Life
science | |
2,480
shares of Series Seed Preferred (converted note) | |
| 15,003 | | |
| 15,391 | | |
|
0.1 |
% |
Total
Preferred stock investments | | |
| |
| |
$ | 3,286,383 | | |
$ | 5,225,498 | | |
|
40.5 |
% |
| |
United States |
| |
| |
| |
$ | 3,036,383 | | |
$ | 4,919,891 | | |
|
38.2 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 200,000 | | |
|
1.5 |
% |
| |
Rest of World |
| |
| |
| |
| 50,000 | | |
| 105,607 | | |
|
0.8 |
% |
Total
Preferred stock investments | | |
| |
| |
$ | 3,286,383 | | |
$ | 5,225,498 | | |
|
40.5 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
Common
stock investments | | |
| |
| |
| | | |
| | |
|
|
|
|
* | |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
$ | 100,000 | | |
$ | 150,000 | | |
|
1.2 |
% |
* | |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
| 100,000 | | |
| 150,000 | | |
|
1.2 |
% |
| |
Kuantsol
Inc |
| |
Technology | |
133.333 Common shares | |
| 25,000 | | |
| 25,000 | | |
|
0.2 |
% |
Total
Common stock investments |
| |
| |
| |
$ | 225,000 | | |
$ | 325,000 | | |
|
2.5 |
% |
| |
United States |
| |
| |
| |
$ | 25,000 | | |
$ | 25,000 | | |
|
0.2 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 300,000 | | |
|
2.3 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
0.0 |
% |
Total
Common stock investments | | |
| |
| |
$ | 225,000 | | |
$ | 325,000 | | |
|
2.5 |
% |
Continued
to next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Schedule
of Investments as of December 31, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value |
| | |
%
of net assets (a) |
|
Public
common stock investments | | |
| |
| |
| | | |
| |
| |
|
|
|
| |
Boardwalk Tech |
| |
Technology | |
75,000 Common shares | |
$ | 65,600 | | |
$ | 70,000 |
| | |
0.5 |
% |
| |
Boardwalk Tech |
| |
Technology | |
150,000 Common shares | |
| 73,500 | | |
| 86,505 |
| | |
0.7 |
% |
| |
Sanaby
Health Acquisition Corp 1 |
| |
Life
science | |
50,000 Common shares | |
| 100,000 | | |
| 473,732 |
| | |
3.7 |
% |
Total
Public common stock investments | |
| |
$ | 239,100 | | |
$ | 630,237 |
| | |
4.9 |
% |
| |
United States |
| |
| |
| |
$ | 239,100 | | |
$ | 630,237 |
| | |
4.9 |
% |
| |
Canada |
| |
| |
| |
| - | | |
| - |
| | |
0.0 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - |
| | |
0.0 |
% |
Total
Public common stock investments | |
| |
$ | 239,100 | | |
$ | 630,237 |
| | |
4.9 |
% |
| |
|
| |
| |
| |
| | | |
| |
| |
|
|
|
SAFE
investments | | |
| |
| |
| | | |
| |
| |
|
|
|
| |
AOA DX inc |
| |
Life science | |
SAFE | |
$ | 50,000 | | |
$ | 50,000 |
| | |
0.4 |
% |
* | |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
* | |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
* | |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
| 100,000 | | |
| 100,000 |
| | |
0.8 |
% |
* | |
Madorra Inc |
* | |
Life science | |
SAFE | |
| 100,000 | | |
| 100,000 |
| | |
0.8 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 75,000 | | |
| 75,000 |
| | |
0.6 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
* | |
Orion Biotechnology Inc. |
* | |
Life science | |
SAFE | |
| 100,000 | | |
| 100,000 |
| | |
0.8 |
% |
* | |
Polymertal
Ltd |
* | |
Technology | |
SAFE | |
| 150,000 | | |
| 150,000 |
| | |
1.2 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 725,000 | | |
$ | 725,000 |
| | |
5.6 |
% |
| |
United States |
| |
| |
| |
| 175,000 | | |
| 175,000 |
| | |
1.3 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 |
| | |
0.8 |
% |
| |
Rest of World |
| |
| |
| |
| 450,000 | | |
| 450,000 |
| | |
3.5 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 725,000 | | |
$ | 725,000 |
| | |
5.6 |
% |
| |
|
| |
| |
| |
| | | |
| |
| |
|
|
|
Other
investments |
| |
| |
| |
| | | |
| |
| |
|
|
|
| |
Enduralock LLC |
| |
Technology | |
34.1 Series A-1 Ownership Units | |
$ | 30,000 | | |
$ | 30,000 |
| | |
0.2 |
% |
| |
Enduralock LLC |
| |
Technology | |
39.7 Series A-1 Ownership Units | |
| 35,000 | | |
| 35,000 |
| | |
0.3 |
% |
| |
Exodos Life Sciences LP |
| |
Life science | |
Class A-1 Preferred Ownership
Units | |
| 206,000 | | |
| 206,000 |
| | |
1.6 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
2,193 Class A-1 Ownership units | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 |
| | |
0.2 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 |
| | |
0.2 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
4,386 Class A-1 Ownership units | |
| 100,000 | | |
| 100,000 |
| | |
0.8 |
% |
| |
Riso Capital Fund I, LP |
| |
Technology | |
Ownership units | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
| |
Riso
Capital Fund I, LP |
| |
Technology | |
Ownership
units | |
| 50,000 | | |
| 50,000 |
| | |
0.4 |
% |
Total
Other investments |
| |
| |
| |
$ | 571,000 | | |
$ | 571,000 |
| | |
4.4 |
% |
| |
United States |
| |
| |
| |
$ | 521,000 | | |
$ | 571,000 |
| | |
4.4 |
% |
| |
Canada |
| |
| |
| |
| - | | |
| - |
| | |
0.0 |
% |
| |
Rest of World |
| |
| |
| |
| 50,000 | | |
| - |
| | |
0.0 |
% |
Total
Other investments |
| |
| |
| |
$ | 571,000 | | |
$ | 571,000 |
| | |
4.4 |
% |
| |
|
| |
| |
| |
| | | |
| |
| |
|
|
|
Total
investments | | |
| |
| |
$ | 8,926,469 | | |
$ | 12,156,511 |
| | |
94.2 |
% |
| |
United States |
| |
| |
| |
$ | 7,031,469 | | |
$ | 9,884,551 |
| | |
76.6 |
% |
| |
Canada |
| |
| |
| |
| 995,000 | | |
| 1,250,091 |
| | |
9.7 |
% |
| |
Rest of World |
| |
| |
| |
| 900,000 | | |
| 1,021,869 |
| | |
7.9 |
% |
Total
investments |
| |
| |
| |
$ | 8,926,469 | | |
$ | 12,156,511 |
| | |
94.2 |
% |
| |
(a) based on total net assets of $ 12,911,623 | |
| | | |
| |
| | |
|
|
( i ) | |
Kyto management sit on the Board of these companies. | |
| | | |
| |
| | |
|
|
* | |
These companies are headquartered outside of the US. | |
| | | |
| |
| | |
|
|
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Schedule
of Investments as of March 31, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
%
of net assets (a) | |
Convertible loan investments |
| |
| |
| |
| | | |
| | | |
| | |
( i ) | |
Achelios Therapeutics
Inc. |
| |
Life science | |
Convertible Note,
8% due, December 2021 | |
$ | 100,000 | | |
$ | 121,173 | | |
| 1.7 | % |
( i ) | |
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note, 8% due December
2021 | |
| 25,000 | | |
| 29,033 | | |
| 0.4 | % |
( i ) | |
Achelios Therapeutics Inc. |
| |
Life science | |
Convertible Note, 8% due December
2021 | |
| 50,000 | | |
| 54,581 | | |
| 0.8 | % |
| |
Avisi Technologies Inc |
| |
Life science | |
Convertible Note, 8% due July
2022 | |
| 50,000 | | |
| 52,674 | | |
| 0.8 | % |
| |
Basepaws Inc |
| |
Life science | |
Convertible Note, 1% due April
2020 | |
| 50,000 | | |
| 162,319 | | |
| 2.3 | % |
( i ) | |
Beam Semiconductor Inc |
* | |
Technology | |
Convertible Note, 8% due April
2022 | |
| 150,000 | | |
| 171,041 | | |
| 2.4 | % |
( i ) | |
Beam Semiconductor Inc |
* | |
Technology | |
Convertible Note, 8% due March
2021 | |
| 50,000 | | |
| 54,285 | | |
| 0.8 | % |
| |
Corinnova Inc |
| |
Life science | |
Convertible Note, 6% due December
2024 | |
| 100,000 | | |
| 102,318 | | |
| 1.5 | % |
| |
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 8% due September
2022 | |
| 30,000 | | |
| 33,768 | | |
| 0.5 | % |
| |
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 8% due February
2023 | |
| 35,000 | | |
| 38,053 | | |
| 0.5 | % |
| |
Cyberdontics Inc |
* | |
Life science | |
Convertible Note, 0% no due
date | |
| 35,000 | | |
| 36,296 | | |
| 0.5 | % |
| |
Deep Blue Medical Advances
Inc |
| |
Life science | |
Convertible Note, 6% due June
2022 | |
| 50,000 | | |
| 50,863 | | |
| 0.7 | % |
| |
Every Key Inc |
| |
Technology | |
Convertible Note, 5% due December
2023 | |
| 100,000 | | |
| 106,521 | | |
| 1.5 | % |
| |
Identical Inc |
| |
Life science | |
Convertible Note, 2% due May
2022 | |
| 100,000 | | |
| 100,844 | | |
| 1.4 | % |
| |
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due October
2020 | |
| 50,000 | | |
| 59,721 | | |
| 0.9 | % |
| |
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due July
2021 | |
| 30,000 | | |
| 34,149 | | |
| 0.5 | % |
| |
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due February
2022 | |
| 50,000 | | |
| 56,640 | | |
| 0.8 | % |
| |
INBay Technology Inc |
* | |
Technology | |
Convertible Note, 12% due December
2022 | |
| 40,000 | | |
| 41,552 | | |
| 0.6 | % |
| |
Kiana Analytics Inc |
| |
Technology | |
Convertible Note, 3% December 2022 | |
| 100,000 | | |
| 100,847 | | |
| 1.4 | % |
| |
Kitotech Medical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 100,000 | | |
| 243,133 | | |
| 3.5 | % |
| |
Kitotech Medical Inc |
| |
Life science | |
Convertible Note, 6% due November
2022 | |
| 75,000 | | |
| 83,738 | | |
| 1.2 | % |
| |
Lifewave Biomedical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 30,000 | | |
| 32,830 | | |
| 0.5 | % |
| |
Lifewave Biomedical Inc |
| |
Life science | |
Convertible Note, 6% due December
2020 | |
| 70,000 | | |
| 74,810 | | |
| 1.1 | % |
| |
Navaux Inc |
| |
Life science | |
Convertible Note, 6% due December
2023 | |
| 60,000 | | |
| 61,036 | | |
| 0.9 | % |
| |
Neuro42 Inc. |
| |
Life science | |
Convertible Note, 8% due December
2023 | |
| 50,000 | | |
| 50,559 | | |
| 0.7 | % |
| |
Octagon Therapeutics Inc |
| |
Life science | |
Convertible Note, 5% due June
2021 | |
| 50,000 | | |
| 51,110 | | |
| 0.7 | % |
| |
Octagon Therapeutics Inc |
| |
Life science | |
Convertible Note, 5% due June
2021 | |
| 50,000 | | |
| 50,966 | | |
| 0.7 | % |
| |
Perikinetics Inc |
| |
Life science | |
Convertible Note, 6% due May
2022 | |
| 100,000 | | |
| 102,318 | | |
| 1.5 | % |
| |
Preview Medical Inc |
| |
Life science | |
Convertible Note, 7% due January
2023 | |
| 100,000 | | |
| 101,918 | | |
| 1.5 | % |
| |
SageMedic Corp |
| |
Life science | |
Convertible Note, 8% April
2021 plus warrants | |
| 50,000 | | |
| 57,879 | | |
| 0.8 | % |
| |
SageMedic Corp |
| |
Life science | |
Convertible Note, 8% December
2022 plus warrants | |
| 75,000 | | |
| 77,086 | | |
| 1.1 | % |
| |
Sensing Electromagnetic Plus
Corp |
| |
Technology | |
Convertible Note, Fully reserved | |
| 50,000 | | |
| 1 | | |
| 0.0 | % |
| |
Sensing Electromagnetic Plus
Corp |
| |
Technology | |
Convertible Note, Fully reserved | |
| 11,048 | | |
| 1 | | |
| 0.0 | % |
| |
Valfix Medical Inc |
* | |
Life science | |
Convertible Note, 8% December 2021 | |
| 50,000 | | |
| 52,510 | | |
| 0.8 | % |
| |
Xpan Inc |
* | |
Life science | |
Convertible Note, 8% due March
2022 | |
| 50,000 | | |
| 54,296 | | |
| 0.8 | % |
| |
Xpan Inc |
* | |
Life science | |
Convertible Note, 8% due June
2022 | |
| 25,000 | | |
| 26,545 | | |
| 0.4 | % |
| |
Xpan
Inc |
* | |
Life
science | |
Convertible
Note, 8% due June 2022 | |
| 25,000 | | |
| 26,540 | | |
| 0.4 | % |
Total Convertible loan investments | |
| |
$ | 2,216,048 | | |
$ | 2,553,954 | | |
| 36.5 | % |
| |
United States |
| |
| |
| |
$ | 1,596,048 | | |
$ | 1,868,557 | | |
| 26.7 | % |
| |
Canada |
| |
| |
| |
| 370,000 | | |
| 407,561 | | |
| 5.8 | % |
| |
Rest of World |
| |
| |
| |
| 250,000 | | |
| 277,836 | | |
| 4.0 | % |
Total Convertible loan investments | |
| |
$ | 2,216,048 | | |
$ | 2,553,954 | | |
| 36.5 | % |
| |
|
| |
| |
| |
| | | |
| | | |
| | |
Preferred stock investments |
| |
| |
| |
| | | |
| | | |
| | |
| |
Altis Biosystems |
| |
Life science | |
22,028 shares of Series Seed Preferred | |
$ | 50,000 | | |
$ | 50,000 | | |
| 0.7 | % |
| |
Astrocyte Pharmaceuticals Inc |
| |
Life science | |
260,756 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
| 1.4 | % |
| |
Cnote Group, Inc |
| |
Fintech | |
84,655 shares of series Seed-2
Preferred (converted SAFE) | |
| 51,500 | | |
| 59,783 | | |
| 0.9 | % |
| |
Cnote Group, Inc |
| |
Fintech | |
93,807 shares of Series Seed-3
Preferred (converted note) | |
| 50,000 | | |
| 66,247 | | |
| 0.9 | % |
| |
Colabs Inc |
| |
Life science | |
147,058 shares of Series A-1 Preferred | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
Connectus Services Ltd |
* | |
Technology | |
31,348 shares of Series Seed Preferred | |
| 100,000 | | |
| 100,000 | | |
| 1.4 | % |
| |
Deep Blue Medical Advances
Inc |
| |
Life science | |
10,474 shares of Series A Preferred | |
| 49,997 | | |
| 49,997 | | |
| 0.7 | % |
| |
Eumentis Thereapeutics Inc |
| |
Life science | |
85,009 shares of Series A Preferred | |
| 100,000 | | |
| 100,000 | | |
| 1.4 | % |
| |
FemtoDX Inc |
| |
Life science | |
42,436 shares of Series A Preferred | |
| 100,000 | | |
| 159,835 | | |
| 2.3 | % |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
i-Lumen Scientific Inc. |
| |
Life science | |
50,000 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
Inhalon Biopharma Inc |
| |
Life science | |
18,843 shares of Series Seed Preferred | |
| 99,997 | | |
| 99,997 | | |
| 1.4 | % |
| |
Light Line Medical Inc |
| |
Life science | |
62,849 shares of Series Seed
Preferred (converted note) | |
| 30,000 | | |
| 38,031 | | |
| 0.5 | % |
| |
Light Line Medical Inc |
| |
Life science | |
141,871 shares of Series Seed
Preferred (converted note) | |
| 70,000 | | |
| 106,049 | | |
| 1.5 | % |
| |
Light Line Medical Inc |
| |
Life science | |
40,323 shares of Series Seed preferred | |
| 25,000 | | |
| 25,000 | | |
| 0.4 | % |
| |
Light Line Medical Inc |
| |
Life science | |
72,464 shares of Series A Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
Lowell Therapeutics Inc |
| |
Life science | |
20,000 shares of Series A Preferred | |
| 50,000 | | |
| 50,000 | | |
| 0.7 | % |
| |
Micronic Technologies Inc |
| |
Technology | |
51,929 shares of Series Seed-1
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
| 1.4 | % |
| |
Neuroflow Inc |
| |
Life science | |
98,684 shares of Series Seed -2 Preferred | |
| 150,000 | | |
| 224,998 | | |
| 3.2 | % |
| |
Neuroflow Inc |
| |
Life science | |
20,429 shares of Series B Preferred | |
| 100,000 | | |
| 212,497 | | |
| 3.0 | % |
| |
New View Surgical, Inc. |
| |
Life science | |
53,825 shares of Series A-1 Preferred | |
| 75,000 | | |
| 75,000 | | |
| 1.1 | % |
Continued
to next page
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Schedule
of Investments as of March 31, 2021
(Unaudited)
| |
Portfolio
Company |
| |
Industry | |
Investment | |
Cost | | |
Fair
value | | |
|
%
of net assets (a) |
|
Preferred stock investments (continued) | |
| |
| | | |
| | |
|
|
|
|
| |
Otomagnetics Inc |
| |
Life science | |
16,538 shares of
Series A-1 Preferred plus warrants | |
$ | 100,000 | | |
$ | 100,000 | | |
|
1.4 |
% |
| |
Promaxo |
| |
Life science | |
104,248 shares of Series B-1
Preferred, (converted note) | |
| 250,000 | | |
| 531,738 | | |
|
7.6 |
% |
| |
Seal Rock Therapeutics, Inc. |
| |
Life science | |
68,075 shares of Series Seed
Preferred, (converted note) | |
| 78,000 | | |
| 80,329 | | |
|
1.1 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
42,657 shares of Series A-1 Preferred | |
| 51,500 | | |
| 97,940 | | |
|
1.4 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
28,147 shares of Series A Preferred
(converted note) | |
| 50,000 | | |
| 64,626 | | |
|
0.9 |
% |
| |
Shyft (FKA Crater Group Inc) |
| |
Technology | |
21,774 shares of Series A-1
Preferred (converted note) | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
50,000 shares of Series B Preferred
plus warrants | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
( i ) | |
Trellis Bioscience LLC |
| |
Life science | |
100,000 shares of Series B
Preferred plus warrants | |
| 100,000 | | |
| 100,000 | | |
|
1.4 |
% |
| |
Valfix Medical Inc |
* | |
Life science | |
27,217 shares of Series Seed Preferred | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
| |
Visgenx Inc |
| |
Life science | |
7,833 shares of Series Seed-1
Preferred (converted note) | |
| 30,000 | | |
| 46,352 | | |
|
0.7 |
% |
| |
Visgenx Inc |
| |
Life science | |
4,132 shares of Series Seed
Preferred (converted note) | |
| 25,000 | | |
| 25,648 | | |
|
0.4 |
% |
| |
Visgenx
Inc |
| |
Life
science | |
2,480
shares of Series Seed Preferred (converted note) | |
| 15,003 | | |
| 15,391 | | |
|
0.2 |
% |
Total
Preferred stock investments |
| |
| |
| |
$ | 2,450,997 | | |
$ | 3,129,458 | | |
|
44.8 |
% |
| |
United States |
| |
| |
| |
$ | 2,300,997 | | |
$ | 2,979,458 | | |
|
42.6 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
|
1.4 |
% |
| |
Rest of World |
| |
| |
| |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
Total
Preferred stock investments |
| |
| |
| |
$ | 2,450,997 | | |
$ | 3,129,458 | | |
|
44.8 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
Common
stock investments |
| |
| |
| |
| | | |
| | |
|
|
|
|
| |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
$ | 100,000 | | |
$ | 150,000 | | |
|
2.1 |
% |
| |
BendaRX Corp |
* | |
Life science | |
12,500 Common shares | |
| 100,000 | | |
| 150,000 | | |
|
2.1 |
% |
| |
Boardwalk
Tech |
| |
Technology | |
150,000 Common shares | |
| 73,500 | | |
| 91,995 | | |
|
1.3 |
% |
Total
Common stock investments |
| |
| |
| |
$ | 273,500 | | |
$ | 391,995 | | |
|
5.6 |
% |
| |
United States |
| |
| |
| |
$ | 73,500 | | |
$ | 91,995 | | |
|
1.3 |
% |
| |
Canada |
| |
| |
| |
| 200,000 | | |
| 300,000 | | |
|
4.3 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
0.0 |
% |
Total
Common stock investments |
| |
| |
| |
$ | 273,500 | | |
$ | 391,995 | | |
|
5.6 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
SAFE
investments |
| |
| |
| |
| | | |
| | |
|
|
|
|
| |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
$ | 50,000 | | |
$ | 50,000 | | |
|
0.7 |
% |
| |
Infinidome Ltd |
* | |
Technology | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 75,000 | | |
| 75,000 | | |
|
1.1 |
% |
| |
Mitre Medical Corp |
| |
Life science | |
SAFE | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
| |
Orion
Biotechnology Inc. |
* | |
Life
science | |
SAFE | |
| 100,000 | | |
| 100,000 | | |
|
1.4 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 325,000 | | |
$ | 325,000 | | |
|
4.6 |
% |
| |
United States |
| |
| |
| |
$ | 125,000 | | |
$ | 125,000 | | |
|
1.8 |
% |
| |
Canada |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
|
1.4 |
% |
| |
Rest of World |
| |
| |
| |
| 100,000 | | |
| 100,000 | | |
|
1.4 |
% |
Total
SAFE investments |
| |
| |
| |
$ | 325,000 | | |
$ | 325,000 | | |
|
4.6 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
Other
investments |
| |
| |
| |
| | | |
| | |
|
|
|
|
| |
Enduralock LLC |
| |
Technology | |
34.1 Series A-1 Ownership Units | |
$ | 30,000 | | |
$ | 30,000 | | |
|
0.4 |
% |
| |
Enduralock LLC |
| |
Technology | |
39.7 Series A-1 Ownership Units | |
| 35,000 | | |
| 35,000 | | |
|
0.5 |
% |
( i ) | |
Exodos Life Sciences LP |
| |
Life science | |
Class A-1 Preferred Ownership
Units | |
| 206,000 | | |
| 206,000 | | |
|
2.9 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
2,193 Class A-1 Ownership units | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
|
0.4 |
% |
| |
Green Sun Medical LLC |
| |
Life science | |
1,096 Class A-1 Ownership units | |
| 25,000 | | |
| 25,000 | | |
|
0.4 |
% |
| |
Riso
Capital Fund I, LP |
| |
Technology | |
Ownership
units | |
| 50,000 | | |
| 50,000 | | |
|
0.7 |
% |
Total
Other investments |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
|
6.0 |
% |
| |
United States |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
|
6.0 |
% |
| |
Canada |
| |
| |
| |
| - | | |
| - | | |
|
0.0 |
% |
| |
Rest of World |
| |
| |
| |
| - | | |
| - | | |
|
0.0 |
% |
Total
Other investments |
| |
| |
| |
$ | 421,000 | | |
$ | 421,000 | | |
|
6.0 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
Total
investments |
| |
| |
| |
$ | 5,686,545 | | |
$ | 6,821,407 | | |
|
97.5 |
% |
| |
United States |
| |
| |
| |
$ | 4,516,545 | | |
$ | 5,486,010 | | |
|
78.4 |
% |
| |
Canada |
| |
| |
| |
| 770,000 | | |
| 907,561 | | |
|
13.0 |
% |
| |
Rest of World |
| |
| |
| |
| 400,000 | | |
| 427,836 | | |
|
6.1 |
% |
Total
investments |
| |
| |
| |
$ | 5,686,545 | | |
$ | 6,821,407 | | |
|
97.5 |
% |
| |
|
| |
| |
| |
| | | |
| | |
|
|
|
|
| |
(a)
based on total net assets of $ 6,993,163 | |
| |
| |
| | | |
| | |
|
|
|
|
( i ) | |
| |
| |
| | | |
| | |
|
|
|
|
* | |
| |
| |
| | | |
| | |
|
|
|
|
The
accompanying notes are an integral part of these condensed interim financial statements.
Kyto
Technology and Life Science, Inc.
Notes
to Unaudited Condensed Financial Statements
December
31, 2021
NOTE
1 – DESCRIPTION OF BUSINESS
Kyto
Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of
B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was
changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company
operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.
The
Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases
and had been evaluating a number of strategies. As of March 31, 2018, the Company had accumulated a deficit of $32,380,746 from all prior
operations. In April 2018, the Board adopted a new business plan focused on the development of early-stage technology and life science
businesses through early-stage investment funding. The Company has recruited a number of experienced investment consultants from a network
that includes angel investors, corporate managers, sophisticated early-stage investors and successful entrepreneurs with experience across
a number of technology and life science products and markets, and relies on input from these advisors in conducting due diligence and
making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment groups and
other sophisticated investors and participates only after these groups have completed due diligence and committed to invest, in effect
becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors. The
Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate
new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s
investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management
or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale
of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally,
it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such
exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions
or an initial public offering (“IPO”) which may result in cash or equity proceeds. Other than making its initial and, potentially,
follow-on investments in its portfolio companies, the Company does not provide any financial support to any of its investees.
The
Company has one regular employee – the CEO, Mr. Paul Russo. Prior to December 31, 2020, he was acting as a consultant to the Company
and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged as an
employee of the Company at a salary of $400,000 per annum of which $100,000 and $300,000 was earned in the three months and nine months
ended December 31, 2021, respectively, of which a balance of $80,000 was deferred at December 31, 2021. No
consulting fees and no options were granted to him during these periods. During the three months and nine months ended December 31, 2020,
Mr. Russo received no payroll or consulting fees, however in the three and nine months ended December 31, 2020, he received a bonus of
$50,000
and was granted options to purchase 215,000
shares of Common stock.
The
Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the
sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result
in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of December 31, 2021,
the Company had approximately $600,000
of cash to cover its operating expenses,
and new investment requirements and is continuing to raise additional funding on a recurring monthly basis. If successful, it will have
sufficient funding for further investments and ongoing operations. However, there is no assurance that the Company will be able to raise
sufficient cash to cover its requirements on attractive terms, if at all, and whether it will be able to continue as a going concern.
These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying condensed
interim financial statements have been prepared assuming the Company will continue to operate as a going concern and do not include any
adjustments that might result from the outcome of this uncertainty. Stay at home orders and general economic uncertainties arising out
of the current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s
business operations, although some of its portfolio investment companies report delays in their programs.
At
March 31, 2020, management determined that the Company was an investment company for purposes of Accounting Standards Codification Topic
946, Financial Services—Investment Companies (ASC Topic 946) disclosure, and adopted the specialized accounting and reporting
guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”) was incorporated in Delaware in December
2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021 for review by the Securities and Exchange
Commission (the “SEC”). KI is an internally managed, closed-end investment company that has elected to be regulated as a
business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately
upon effectiveness of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As
of the completion of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the
Securities Act and may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the
merger, the Company had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3(c)(1).
As
a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for
U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code
of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The
Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final
approval of its registration as at the filing date of this report.
NOTE
2 - BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
(A)
BASIS OF PRESENTATION
The
accompanying unaudited condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles
(“U.S. GAAP”) for interim financial information with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly,
these unaudited condensed financial statements do not include all of the information and disclosures required by U.S. GAAP for complete
financial statements. In the opinion of management, the accompanying unaudited condensed financial statements include all adjustments
(consisting only of normal recurring adjustments), which the Company considers necessary, for a fair presentation of those financial
statements. The results of operations and cash flows for the three months and nine months ended December 31, 2021 may not necessarily
be indicative of results that may be expected for any succeeding quarter or for the entire fiscal year. The condensed balance sheet as
of March 31, 2021 was derived from the audited financial statements at that date, but does not include all the information and footnotes
required by U.S. GAAP. The information contained in this Quarterly Report on Form 10-Q should be read in conjunction with the audited
financial statements of the Company for the year ended March 31, 2021, included in the Annual Report on Form 10-K as filed with the SEC
on August 10, 2021.
The
Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of estimates,
assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those estimates, assumptions,
and judgments. Significant items subject to such estimates will include determining the fair value of investments, revenue recognition,
income tax uncertainties, stock-based compensation, and other contingencies.
The
Company’s financial statements are prepared using the specialized accounting principles of ASC Topic 946. In accordance
with this specialized accounting guidance, the Company recognizes and carries all of its investments at fair value with changes in fair
value recognized in earnings. Additionally, the Company will not apply consolidation or equity method of accounting to its investments.
The carrying amount of the Company’s financial instruments such as cash and payables approximates fair value due to the short maturity
of such instruments. Net assets are calculated as the carrying amounts of assets, including the fair value of investments, less the carrying
amounts of its liabilities.
(B)
RESTATEMENT OF PREVIOUSLY ISSUED FINANCIAL STATEMENTS
The
Company’s previously issued financial statements as of and for three and six months ended September 30, 2021 and the three
months ended June 30, 2021 have been restated to reflect the dividends attributable for the Class B-1, B-2 and B-3
Preferred Stock. The Class B-1, B-2 and B-3 Preferred Stock have cumulative dividends amounting to $98,968 and $350,694 for
three and six months ended September 30, 2021, respectively, and $251,726 for
the three months ended June 30, 2021. Previously, the Company did not present the cumulative dividends attributable to
Class B-1, B-2 and B-3 Preferred Stock in its calculation of earnings (loss) per common share. To
correct this misstatement, the Company has included dividends attributable to Class B-1, B-2 and B-3 Preferred Stock
for the three and six months ended September 30, 2021 and three months ended June 30, 2021, in its calculation of earnings (loss)
per common share below, resulting in a decrease of net income and increase in net loss attributable to common shareholders.
There has been no change in the Company’s total assets, liabilities or operating results.
The
correction of the errors is as follows:
SCHEDULE
OF CORRECTION OF THE ERRORS
| |
| | |
| | |
| |
| |
For the three months ended | | |
For the six months ended | |
| |
September 30,
2021 | | |
June 30,
2021 | | |
September 30,
2021 | |
Net increase (decrease) in net assets resulting from operations | |
$ | 996,133 | | |
$ | (333,792 | ) | |
$ | 662,341 | |
Less: Dividends attributable to Class B-1, B-2 & B-3 stockholders | |
| (98,968 | ) | |
| (251,726 | ) | |
| (350,694 | ) |
Net increase (decrease) in net assets resulting from operations
attributable to Common Shareholders (as restated) | |
$ | 897,165 | | |
$ | (585,518 | ) | |
$ | 311,647 | |
| |
| | | |
| | | |
| | |
As restated: | |
| | | |
| | | |
| | |
Weighted Average Common Shares | |
| 13,273,871 | | |
| 13,268,871 | | |
| 13,270,794 | |
Weighted Average Fully Diluted Shares | |
| 27,500,194 | | |
| 13,268,871 | | |
| 22,228,602 | |
Basic Earnings (Loss) per common share | |
$ | 0.07 | | |
$ | (0.04 | ) | |
$ | 0.02 | |
Diluted Earnings (Loss) per common share | |
$ | 0.04 | | |
$ | (0.04 | ) | |
$ | 0.01 | |
| |
| | | |
| | | |
| | |
As reported: | |
| | | |
| | | |
| | |
Weighted Average Common Shares | |
| 13,271,996 | | |
| 13,268,871 | | |
| 13,269,764 | |
Weighted Average Fully Diluted Shares | |
| 27,338,695 | | |
| 13,268,871 | | |
| 26,263,218 | |
Basic Earnings (Loss) per common share | |
$ | 0.08 | | |
$ | (0.03 | ) | |
$ | 0.05 | |
Diluted Earnings (Loss) per common share | |
$ | 0.04 | | |
$ | (0.03 | ) | |
$ | 0.03 | |
(C)
INVESTMENT TRANSACTIONS AND NET REALIZED AND UNREALIZED GAIN OR LOSS ON INVESTMENTS
The
Company generates increases or decreases in its net assets from the sale of complete or partial investments following a merger or acquisition
(“M&A”) transaction or restructuring or from the revaluation of portfolio company investments to recognize changes in
their fair value, either upwards or downwards. As a minority early-stage investor, the Company does not have the ability to manage the
timing or acceptance of liquidity events that will realize its investments, nor the ability to predict when they may happen, although
as a general guideline, it would expect such events to occur approximately four to five years after its investments are made. The Company
records the realized gains and losses from investment activities upon completion of sale and receipt of net proceeds, after deducting
related transaction expenses. Realized gains or losses on the sale of investments, or upon the determination that an investment balance,
or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains
or losses by calculating the difference between the net proceeds from the repayment or sale and the cost basis of the investment. Net
change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments
during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses
are realized. The Company is in periodic contact with the management of its portfolio investment companies to provide a basis for valuation
changes. The Company does not expect to receive interest and principal repayments on its convertible notes and generally expects these
notes to convert into equity securities upon completion of qualified subsequent financings. Accrued interest is recorded as an adjustment
to the fair value of the convertible notes.
(D)
INCOME TAXES
The
Company accounts for income taxes under the Financial Accounting Standards Accounting Standard Codification Topic 740 “Accounting
for Income Taxes” (“Topic 740”). Under Topic 740, deferred tax assets and liabilities are recognized for the future
tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and
their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income
in the years in which those temporary differences are expected to be recovered or settled. Under Topic 740, the effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period, which includes the enactment date.
(E)
USE OF ESTIMATES
In
preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during
the period presented. Actual results may differ from these estimates.
Significant
estimates during the three months and nine months ended December 31, 2021 and March 31, 2021 include the valuation of the investment
portfolio, deferred tax assets, tax valuation allowance, stock options and warrants.
(F)
CASH AND CASH EQUIVALENTS
The
Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents.
There were no cash equivalents at December 31, 2021 and March 31, 2021, respectively.
(G)
CONCENTRATIONS
The
Company maintains its cash in bank checking and deposit accounts, which, at times, may exceed federally insured limits. As of December
31, 2021, and March 31, 2021, the Company’s bank balance exceeded the federally insured limit by approximately $360,000 and $1.2
million, respectively. The Company has not experienced any losses in such accounts through December 31, 2021.
(H)
STOCK-BASED COMPENSATION
Financial
Accounting Standards Board Accounting Standards Codification Topic 718, “Stock Compensation” requires generally that
all equity awards granted to employees and consultants be accounted for at fair value. This fair value is measured at grant date for
stock settled awards, and at subsequent exercise or settlement for cash-settled awards. Under this method, the Company records an expense
equal to the fair value of the options or warrants issued. The fair value is computed using the Black Scholes options pricing model.
The Company granted consultants and advisors 1,550,000 and 217,500 options during the three months ended December 31, 2021 and December
31, 2020, and 2,290,000 and 847,500 options during the nine months ended December 31, 2021 and December 31, 2020, respectively.
(I)
NET EARNINGS (LOSS) PER COMMON SHARE
In
accordance with Statement of Financial Accounting Standards Accounting Standard Codification Topic 260, “Earnings per Share”,
the Company uses the two-class method to compute net income (loss) per common share because the Company has issued securities,
other than common stock, that contractually entitle the holders to participate in dividends and earnings of the Company. The two-class
method requires earnings for the period to be allocated between common stock and participating securities based upon their respective
rights to receive distributed and undistributed earnings. Holders of Class B-1, B-2 and B-3 of the Company’s convertible preferred
stock are entitled to participate in distributions, when and if declared by the board of directors, that are made to common stockholders
and, as a result, are considered participating securities. As of December 31, 2021, convertible preferred stock dividends totaling $482,693
were accumulated and in arrears. As the Company’s
Board of Directors had not declared such dividends payable, the Company has not recognized such dividend payable liability as of December
31, 2021, and will not recognize such dividend liability until they are declared by the Company’s Board of Directors. Notwithstanding,
the Company has presented such dividend value as a component of the net increase (decrease) in net assets resulting from operations attributable
to common shareholders in the calculation of basic and diluted earnings (loss) per common share.
Under
the two-class method, for periods with net income, basic net income per share of common stock is computed by dividing the net income
attributable to shares of common stock by the weighted average number of shares of common stock outstanding during the period. Net income
attributable to shares of common stock is computed by subtracting from net income the portion of current period earnings that participating
securities would have been entitled to receive pursuant to their dividend rights had all of the period’s earnings been distributed.
No such adjustment to earnings is made during periods with a net loss as the holders of the participating securities have no contractual
obligation to fund losses. Diluted net income per share of common stock is computed under the two-class method by using the weighted
average number of shares of common stock outstanding plus the potential dilutive effects of stock options, warrants and non-participating
convertible preferred shares (Class A and B). In addition, the Company analyzes the potential dilutive effect of the outstanding convertible
securities under the if-converted method when calculating diluted income per share of common stock in which it is assumed that the outstanding
convertible securities convert into common stock at the beginning of the period or date of issuance, if the convertible security was
issued during the period. The Company reports the more dilutive of the approaches (two-class or if-converted) as its diluted net income
per share of common stock during the period.
The
following table sets out the number of shares used in calculating fully-diluted earnings per common share:
SCHEDULE OF EARNINGS PER SHARE
Weighted
average method
Number
of shares used in calculating fully diluted earnings per common shares (two-class method)
| |
Three months to December 31, 2021 | | |
Nine months to December 31, 2021 | |
Common stock | |
| 13,287,621 | | |
| 13,273,038 | |
Class A Preferred Stock | |
| 4,200,000 | | |
| 4,200,000 | |
Class B Preferred Stock | |
| 286,250 | | |
| 286,250 | |
Options | |
| 4,145,500 | | |
| 3,044,305 | |
Warrants | |
| 1,596,667 | | |
| 1,596,667 | |
| |
| | | |
| | |
Total shares used in calculating fully-diluted earnings per common share, two-class method | |
| 23,516,038 | | |
| 22,400,260 | |
Weighted
average method
Number
of shares used in calculating fully diluted earnings per common shares (if-converted method)
| |
Three months to December 31, 2020 | | |
Nine months to December 31, 2020 | |
Common stock | |
| 8,528,007 | | |
| 5,836,831 | |
Class A Preferred Stock | |
| 4,200,000 | | |
| 4,200,000 | |
Class B Preferred Stock | |
| 2,789,954 | | |
| 1,933,912 | |
Options | |
| 2,157,500 | | |
| 1,842,873 | |
Warrants | |
| 1,596,667 | | |
| 3,329,067 | |
| |
| | | |
| | |
Total shares used in calculating fully-diluted earnings per common share, if-converted method | |
| 19,272,128 | | |
| 17,142,683 | |
(J)
INVESTMENT AND VALUATION OF INVESTMENT AT FAIR VALUE
The
Company reviews the performance of its investments based on available information, including management reports, press releases, web
site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports,
to determine their fair values. In the event that management considers the fair value of an investment to be greater or less than the
current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.
The
Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,
“Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC
820 establishes a common definition for fair value to be applied to existing U.S. GAAP that require the use of fair value measurements
which establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market
participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The
Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed
and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available.
In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active,
the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances,
which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For
investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated
by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation
of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive
those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves
comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example
the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These
valuation methodologies involve a significant degree of judgment on the part of our management and board.
In
determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may
include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market
yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral,
the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business,
comparisons of financial ratios of peer companies that are public, merger and acquisition comparable, the principal market and enterprise
values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The
estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence
of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments,
the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments
existed.
The
authoritative accounting guidance prioritizes the use of market-based inputs over entity-specific inputs and establishes a three-level
hierarchy for fair value measurements based upon the transparency of inputs to the valuation. The three levels of valuation hierarchy
are defined as follows:
Level
1: Observable inputs such as quoted market prices in active markets for identical assets or liabilities
Level
2: Observable market-based inputs or unobservable inputs that are corroborated by market data
Level
3: Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions.
Most of the Company’s investments are Level 3.
Critical
accounting policies and practices are the policies that are both most important to the portrayal of the Company’s financial condition
and results, and require management’s most difficult, subjective, or complex judgments, often as a result of the need to make estimates
about matters that are inherently uncertain. These include estimates of the fair value of Level 3 investments and other estimates that
affect the reported amounts of assets and liabilities as of the date of the financial statements and the reported amounts of certain
revenues and expenses during the reporting period. It is likely that changes in these estimates will occur in the near term. The Company’s
estimates are inherently subjective in nature and actual results could differ materially from such estimates. See “Note 1 –
Significant Accounting Policies” to our financial statements as of March 31, 2021, as filed with the SEC on August 10, 2021, for
further detail regarding our critical accounting policies and recently issued or adopted accounting pronouncements.
(K)
RECENT ACCOUNTING PRONOUNCEMENTS
Management
does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect
on the accompanying financial statements.
(L)
OTHER ASSETS
Other assets principally include deferred offering costs. Since April 2019, the Company has conducted a series of sales of common and
preferred stock to fund its ongoing investment program and cost of operations. Typically, it expects that raising capital through the
sale of any series of securities, from start to finish, may take from six to nine months and in order to match the cost and benefits
of this process, the Company adopted a policy of capitalizing direct expenses incurred in the course of raising capital, with the intention
of netting accumulated expenses against proceeds from sale of equity, and reporting the net funds raised at the close. Direct expenses
include legal fees, investor relations fees, investor roadshows and meeting expenses, and related filing and printing fees. At December
31, 2021 and March 31, 2021, the Company had deferred $293,564 and $169,891, respectively, of such expenses, relating to the preparation
and filing of an N-2 Registration Statement.
NOTE
3 – COMMITMENTS AND CONTINGENCIES
The
Company has no commitments or contingencies as of the date of this filing. The Company may be subject to litigation during the normal
course of business but has not received any such claims to date.
NOTE
4 - RELATED PARTY TRANSACTIONS
At
December 31, 2021 and March 31, 2021, the Company had accrued and owed $83,000 and $51,420, respectively, to officers of the Company
for deferred payroll and consulting service fees.
At
December 31, 2021, officers or directors of the Company held board positions at four portfolio companies: Beam Semiconductor Inc., Achelios
Therapeutics Inc., Trellis Bioscience LLC and INBay Technology Inc. At March 31, 2021, officers or directors of the Company held board
positions at four portfolio companies: Beam Semiconductor Inc., Achelios Therapeutics Inc., Trellis Bioscience LLC and Exodos Life Sciences
LP.
NOTE
5 – INVESTMENTS
The
following table summarizes the Company’s investment portfolio at December 31, 2021 and March 31, 2021.
SUMMARY OF INVESTMENT PORTFOLIO
| |
December 31, 2021 | | |
| | | |
March 31, 2021 | | |
| | |
Number of portfolio companies | |
| 69 | | |
| | | |
| 51 | | |
| | |
Fair value | |
$ | 12,156,511 | | |
| | | |
$ | 6,821,407 | | |
| | |
Cost | |
| 8,926,469 | | |
| | | |
| 5,686,545 | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
% of portfolio at fair value | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
| 4,679,776 | | |
| 38.4 | % | |
| 2,553,954 | | |
| 37.4 | % |
Preferred stock | |
| 5,225,498 | | |
| 43.0 | % | |
| 3,129,458 | | |
| 45.9 | % |
Common stock | |
| 955,237 | | |
| 7.9 | % | |
| 391,995 | | |
| 5.7 | % |
SAFE | |
| 725,000 | | |
| 6.0 | % | |
| 325,000 | | |
| 4.8 | % |
Other ownership units | |
| 571,000 | | |
| 4.7 | % | |
| 421,000 | | |
| 6.2 | % |
Total | |
$ | 12,156,511 | | |
| 100.0 | % | |
$ | 6,821,407 | | |
| 100.0 | % |
A
SAFE is a Simple Agreement for Future Equity in the form of a warrant to purchase equity stock in a future priced round.
Our
investment portfolio represents approximately 94%
and 97%
of our net assets at December 31, 2021 and March
31, 2021, respectively. Investments in early-stage start-up private operating entities are valued based on available metrics,
such as relevant market multiples and comparable company valuations, company specific-financial data including subsequent financings,
actual and projected results, and independent third-party valuation estimates.
Significant
Unobservable Inputs for Level 3 Assets and Liabilities
In
accordance with FASB ASC 820, Fair Value Management, the tables below provide quantitative information about the Company’s
fair value measurements of its Level 3 assets as of December 31, 2021 and March 31, 2021. In addition to the techniques and inputs noted
in the tables above, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies
when determining the Company’s fair value measurements. The tables below are not meant to be all-inclusive, but rather provide
information on the significant Level 3 inputs as they relate to the Company’s fair value measurements. To the extent an unobservable
input is not reflected in the tables below, such input is deemed insignificant with respect to the Company’s Level 3 fair value
measurements. Significant changes in the inputs in isolation would result in a significant change in the fair value measurement, depending
on the materiality of the investment.
The
following table summarizes the valuation techniques and significant unobservable inputs used for investments that are categorized within
Level 3 of the fair value hierarchy as of December 31, 2021 and March 31, 2021:
SCHEDULE OF INVESTMENTS
| | |
As
of December 31, 2021 | |
| | |
Fair
Value | | |
Valuation
Approach/ Technique | |
Unobservable
Inputs | | |
Range/
Weighted
Average | |
| | |
| | |
| |
| | |
| |
Convertible notes:
Basepaws Inc | | |
$ | 394,980 | | |
Market approach
based on indicative term sheet and last round of financing | |
| As
if converted note and Series A term sheet of $37.5 million | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Convertible notes: Cyberdontics
Inc | | |
| 190,422 | | |
Valuation based on indicative
securities transaction using a backsolve calculation to approximate value. | |
| Market
cap of $12 million on current SAFE offering applied to cap table | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Convertible notes: Promaxo
Inc | | |
| 185,136 | | |
Market approach based on
available comparables and financial performance | |
| Conversion
prospects, market yield, remaining maturity | | |
| 5%
yield | |
| | |
| | | |
| |
| | | |
| | |
Convertible notes: Other | | |
| 3,909,238 | | |
Market approach based on
available comparables and financial performance | |
| Conversion
prospects, market yield, remaining maturity | | |
| 1-12%
yield | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
company: Inhalon Inc | | |
| 256,198 | | |
Valuation based on indicative
securities transaction using a backsolve calculation to approximate value. | |
| Market
cap of $40 million on current note offering, and cap table | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
company: Neuroflow Inc | | |
| 676,882 | | |
Valuation based on indicative
securities transaction using a backsolve calculation to approximate value. | |
| Weighting
applied to $17 million valuation and 6-7x forecast revenue | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
company: Valfix Inc | | |
| 105,607 | | |
Valuation based on indicative
securities transaction using a backsolve calculation to approximate value. | |
| Market
value of $29.5 million invested capital applied to cap table | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
companies Shyft Moving Inc | | |
| 269,820 | | |
Market approach based on
indicative term sheet and last round of financing | |
| 50/50
weighting to prior A-3 preferred and indicated pre Series B price. Forecast revenue from
investor deck and 75% percentile for public company peer valuation ratios | | |
| Based
on Series B valuation of $80 million | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
companies: Seal Rock Therapeutics Inc | | |
| 199,375 | | |
Market approach based on
indicative term sheet and last round of financing | |
| 50/50
weighting to prior series seed preferred and indicated note price. 75% percentile for public
company peer valuation ratios | | |
| Based
on new note indication of $80 million | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
companies: Femto DX Inc | | |
| 290,046 | | |
Market approach based on
indicative term sheet and last round of financing | |
| 50/50
weighting to prior series B-2 preferred price and public market. 75% percentile for public
company peer valuation ratios | | |
| Based
on Series B valuation of $170 million | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
companies: Promaxo Inc | | |
| 1,034,684 | | |
Market approach based on
available comparables and financial performance | |
| a)
Last round of financing for series B-2 price, 118% change in enterprise value at 75th percentile;
b) revenue multiples 2021 13.3x 2022 9.3x | | |
| 0%-168.3%
0.6x - 27.7x
0.5x - 59.4x | |
| | |
| | | |
| |
| | | |
| | |
Preferred stock in private
companies: Other | | |
| 2,392,886 | | |
Market approach based on
available comparables and financial performance | |
| Market
approach based on available information from portfolio companies | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Common stock in private companies | | |
| 325,000 | | |
Market approach based on
available comparables and financial performance | |
| Historic
or projected revenue and/or EBITDA multiples discounted for lack of marketability | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
SAFE | | |
| 725,000 | | |
Market approach based on
available comparables and financial performance | |
| Precedent
and follow-on transactions adjusted for marketability | | |
| Various | |
| | |
| | | |
| |
| | | |
| | |
Total Investments | | |
$ | 10,955,274 | | |
| |
| | | |
| | |
| |
As
of March 31, 2021 | |
| |
Fair
Value | | |
Valuation
Approach/ Technique | |
Unobservable
Inputs | |
Range/
Weighted Average |
| |
| | |
| |
| |
|
Convertible
notes: Kitotech Medical Inc | |
| 326,871 | | |
Market
approach based on available comparables and financial performance | |
Market
cap of $28.51 million a public company 75th percentile as if converted 2020 note | |
Range
: $28.514 million |
| |
| | | |
| |
| |
|
Convertible
notes | |
| 2,227,083 | | |
Market
approach based on available comparables and financial performance | |
Conversion
prospects, market yield, remaining maturity | |
1-12%
yield |
| |
| | | |
| |
| |
|
Preferred
stock in private companies: Femto DX Inc | |
| 159,835 | | |
Market
approach based on available comparables and financial performance | |
Based
on Series B financing and public company peer multiples using 50:50 percentile | |
Market
value of invested capital $58.66 million |
| |
| | | |
| |
| |
|
Preferred
stock in private companies: Neuroflow Inc | |
| 437,495 | | |
Market
approach based on available comparables and financial performance | |
Based
on Series Seed 2 and last round of financing - Series B | |
Market
value of invested capital $57.98 million |
| |
| | | |
| |
| |
|
Preferred
stock in private companies: other | |
| 2,532,128 | | |
Market
approach based on available comparables and financial performance | |
Market
approach based on available information from portfolio companies | |
Various |
| |
| | | |
| |
| |
|
Common
stock in private companies | |
| 300,000 | | |
Market
approach based on available comparables and financial performance | |
Historic
or projected revenue and/or EBITDA multiples | |
Various |
| |
| | | |
| |
| |
|
SAFE | |
| 325,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
| |
| | | |
| |
| |
|
Other
investments | |
| 421,000 | | |
Market
approach based on available comparables and financial performance | |
Precedent
and follow-on transactions adjusted for marketability | |
Various |
Total
Investments | |
| 6,729,412 | | |
| |
| |
|
The
following table presents fair value measurements of investments, by major class, as of December 31, 2021, and March 31, 2021, according
to the fair value hierarchy:
SCHEDULE OF INVESTMENTS AT FAIR VALUE MEASUREMENTS OF INVESTMENTS
Description | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
| |
As of December 31, 2021 | |
| |
Quoted prices in
active markets for
identical securities | | |
Significant other
observable inputs | | |
Significant
unobservable inputs | | |
| |
Description | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
Investments at Fair Value | |
| | | |
| | | |
| | | |
| | |
Private Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
$ | - | | |
$ | - | | |
$ | 4,679,776 | | |
$ | 4,679,776 | |
Preferred stock | |
| - | | |
| - | | |
| 5,225,498 | | |
| 5,225,498 | |
Common stock | |
| - | | |
| - | | |
| 325,000 | | |
| 325,000 | |
SAFEs | |
| - | | |
| - | | |
| 725,000 | | |
| 725,000 | |
| |
| - | | |
| - | | |
| 10,955,274 | | |
| 10,955,274 | |
Public Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Common stock | |
| 630,237 | | |
| - | | |
| - | | |
| 630,237 | |
| |
| | | |
| | | |
| | | |
| | |
Total Investments at Fair value | |
$ | 630,237 | | |
$ | - | | |
$ | 10,955,274 | | |
$ | 11,585,511 | |
All
investments were treated as Level 3 at December 31, 2021 with the exception of four companies, two of which are invested in common stock
of the public companies and treated as Level 1 and two of which valued at net asset value (NAV) as practical expedient and valued at
$571,000.
Description | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
| |
As of March 31, 2021 | |
Description | |
Level 1 | | |
Level 2 | | |
Level 3 | | |
Total | |
March 31, 2021 | |
| | | |
| | | |
| | | |
| | |
Investments at Fair Value | |
| | | |
| | | |
| | | |
| | |
Private Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Convertible notes | |
$ | - | | |
$ | - | | |
$ | 2,553,954 | | |
$ | 2,553,954 | |
Preferred stock | |
| - | | |
| - | | |
| 3,129,458 | | |
| 3,129,458 | |
Common stock | |
| - | | |
| - | | |
| 300,000 | | |
| 300,000 | |
SAFEs | |
| - | | |
| - | | |
| 325,000 | | |
| 325,000 | |
Other ownership interests | |
| - | | |
| - | | |
| 421,000 | | |
| 421,000 | |
| |
| - | | |
| - | | |
| 6,729,412 | | |
| 6,729,412 | |
| |
| | | |
| | | |
| | | |
| | |
Public Portfolio Companies | |
| | | |
| | | |
| | | |
| | |
Common stock | |
| 91,995 | | |
| - | | |
| - | | |
| 91,995 | |
| |
| | | |
| | | |
| | | |
| | |
Total Investments at Fair value | |
$ | 91,995 | | |
$ | - | | |
$ | 6,729,412 | | |
$ | 6,821,407 | |
We
focus on making our investments in the United States, Canada, and Israel. All investments are made and reported in U.S. dollars. Assets
that are denominated in foreign currencies are translated into U.S. dollars at closing rates of exchange on the date of valuation. Transactions
during the year are translated at the rate of exchange prevailing on the date of the transaction. The Company does not isolate that portion
of results of operations resulting from the changes in foreign exchange rates on securities from fluctuations resulting from changes
in market prices of such securities. Such foreign currency translation gains and losses are included in the net realized gains or losses
from investments and net changes in unrealized gain or losses from investments on the statement of operations.
SCHEDULE OF INVESTMENTS IN UNREALIZED GAIN OR LOSSES FOREIGN EXCHANGE RATES ON SECURITIES
| |
America | | |
Canada | | |
Rest of World | | |
Total | |
Fair value beginning of year March 31, 2021 | |
$ | 5,486,011 | | |
$ | 907,560 | | |
$ | 427,836 | | |
$ | 6,821,407 | |
New investments | |
| 2,653,478 | | |
| 225,000 | | |
| 450,000 | | |
| 3,328,478 | |
Proceeds from sale of investments | |
| (88,554 | ) | |
| - | | |
| - | | |
| (88,554 | ) |
Net change in unrealized gains included in condensed Statements of Operations | |
| 1,833,616 | | |
| 117,531 | | |
| 144,033 | | |
| 2,095,180 | |
Fair value end of nine months December 31, 2021 | |
$ | 9,884,551 | | |
$ | 1,250,091 | | |
$ | 1,021,869 | | |
$ | 12,156,511 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 2,095,180 | |
| |
America | | |
Canada | | |
Rest of World | | |
Total | |
Fair value beginning of year March 31, 2020 | |
$ | 2,170,499 | | |
$ | 245,000 | | |
$ | 250,000 | | |
$ | 2,665,499 | |
New investments | |
| 1,935,000 | | |
| 425,000 | | |
| 50,000 | | |
| 2,410,000 | |
Net change in unrealized gains included in condensed Statements of Operations | |
| 656,188 | | |
| 129,374 | | |
| 21,381 | | |
| 806,943 | |
Fair value end of nine months December 31, 2020 | |
$ | 4,761,687 | | |
$ | 799,374 | | |
$ | 321,381 | | |
$ | 5,882,442 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 806,943 | |
Working
on the experience of our technical advisors, we limit our investments to fintech, technology, and life sciences.
| |
Fintech | | |
Technology | | |
Life science | | |
Total | |
Fair value beginning of year March 31, 2021 | |
$ | 126,030 | | |
$ | 1,394,318 | | |
$ | 5,301,059 | | |
$ | 6,821,407 | |
New investments | |
| - | | |
| 815,600 | | |
| 2,512,878 | | |
| 3,328,478 | |
Proceeds from sale of investments | |
| - | | |
| - | | |
| (88,554 | ) | |
| (88,554 | ) |
Net change in unrealized gains included in condensed Statements of Operations | |
| - | | |
| 61,179 | | |
| 2,034,001 | | |
| 2,095,180 | |
Fair value end of nine months December 31, 2021 | |
$ | 126,030 | | |
$ | 2,271,097 | | |
$ | 9,759,384 | | |
$ | 12,156,511 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 2,095,180 | |
| |
Fintech | | |
Technology | | |
Life science | | |
Total | |
Fair value beginning of year March 31, 2020 | |
$ | 101,500 | | |
$ | 685,002 | | |
$ | 1,878,997 | | |
$ | 2,665,499 | |
Fair value beginning | |
$ | 101,500 | | |
$ | 685,002 | | |
$ | 1,878,997 | | |
$ | 2,665,499 | |
New investments | |
| - | | |
| 325,000 | | |
| 2,085,000 | | |
| 2,410,000 | |
Net change in unrealized gains included in condensed Statements of Operations | |
| 24,530 | | |
| 74,158 | | |
| 708,255 | | |
| 806,943 | |
Fair value end of nine months December 31, 2020 | |
$ | 126,030 | | |
$ | 1,084,160 | | |
$ | 4,672,252 | | |
$ | 5,882,442 | |
Fair value ending | |
$ | 126,030 | | |
$ | 1,084,160 | | |
$ | 4,672,252 | | |
$ | 5,882,442 | |
Changes in unrealized gains or losses for the period included in Condensed Statement of Operations for assets held at the end of the reporting period. | |
| | | |
| | | |
| | | |
$ | 806,943 | |
We
invest in early-stage private companies developing products or solutions in the fields of fintech, technology and life sciences. Typically,
we are investing in interest bearing notes that may be convertible into equity securities upon the completion of qualified subsequent
financings, preferred stock, SAFEs or other forms of ownership. Typically notes carry a two-year term and are then rolled over for additional
periods if no other maturity triggers have been achieved. If a convertible note investment were, in our judgment, to become impaired,
we would reverse the accrued interest and adjust the valuation to reflect management’s assessment of fair value. If a convertible
note investment exceeds its maturity date we would request the portfolio company to document an extension, as well as consider whether
the overdue note, along with all other available performance data and management reviews lead us to consider whether there should be
an adjustment in fair value of the investment. There were no transfers into or out of Level 3 during the three and nine months ended
December 31, 2021 and December 31, 2020.
SCHEDULE OF ADJUSTMENT IN FAIR VALUE TO REFLECT IMPAIRMENT OF INVESTMENT
| |
Convertible
notes | | |
Preferred
stock | | |
Common
stock | | |
SAFEs | | |
Other
ownership interests | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Fair value March
31, 2021 | |
$ | 2,553,954 | | |
$ | 3,129,458 | | |
$ | 391,995 | | |
$ | 325,000 | | |
$ | 421,000 | | |
$ | 6,821,407 | |
Conversions into preferred stock | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
New investments | |
| 1,752,491 | | |
| 835,387 | | |
| 190,600 | | |
| 400,000 | | |
| 150,000 | | |
| 3,328,478 | |
Proceeds
from sale of investments | |
| (88,554 | ) | |
| | | |
| - | | |
| - | | |
| - | | |
| (88,554 | ) |
Unrealized
gains included in condensed Statements of Operations | |
| 461,885 | | |
| 1,260,653 | | |
| 372,642 | | |
| - | | |
| - | | |
| 2,095,180 | |
Fair
value December 31, 2021 | |
$ | 4,679,776 | | |
$ | 5,225,498 | | |
$ | 955,237 | | |
$ | 725,000 | | |
$ | 571,000 | | |
$ | 12,156,511 | |
| |
Convertible
notes | | |
Preferred
stock | | |
Common
stock | | |
SAFEs | | |
Other
ownership interests | | |
Total | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Fair value March
31, 2020 | |
$ | 1,528,002 | | |
$ | 701,497 | | |
$ | 126,500 | | |
$ | 73,500 | | |
$ | 236,000 | | |
$ | 2,665,499 | |
Fair value, beginning | |
$ | 1,528,002 | | |
$ | 701,497 | | |
$ | 126,500 | | |
$ | 73,500 | | |
$ | 236,000 | | |
$ | 2,665,499 | |
Conversions into preferred
stock | |
| (597,984 | ) | |
| 678,313 | | |
| - | | |
| (80,329 | ) | |
| - | | |
| - | |
New investments | |
| 935,000 | | |
| 1,025,000 | | |
| 200,000 | | |
| 150,000 | | |
| 100,000 | | |
| 2,410,000 | |
Unrealized
gains included in condensed Statements of Operations | |
| 556,954 | | |
| 67,665 | | |
| 65,495 | | |
| 81,829 | | |
| 35,000 | | |
| 806,943 | |
Fair
value December 31, 2020 | |
$ | 2,421,972 | | |
$ | 2,472,475 | | |
$ | 391,995 | | |
$ | 225,000 | | |
$ | 371,000 | | |
$ | 5,882,442 | |
Fair
value, ending | |
$ | 2,421,972 | | |
$ | 2,472,475 | | |
$ | 391,995 | | |
$ | 225,000 | | |
$ | 371,000 | | |
$ | 5,882,442 | |
NOTE
6 – EQUITY
A)
PREFERRED STOCK
Class
A
The
Company has sold 4,200,000
Class A Stock Units (“Units”) consisting of one share of Class A Preferred Stock (“Class A”) designated at a
par value of $0.01
per share and one warrant to purchase a share of Common Stock at $0.80
per share. The Units were sold in a private placement to accredited investors. The Class A will be converted into shares of Common
Stock upon listing of the Company on Nasdaq or NYSE. In the event of any liquidation or winding up of the Company, the holders of
the Class A shall be entitled to receive in preference to the holders of shares of Common Stock a per share amount equal to two
times (2x) their original purchase price plus any declared but unpaid dividends. All share issuances and obligations are recognized
on the books and stock register.
On
March 2, 2021, in preparation for an intended IPO, the Company made an offer to all its preferred stockholders to protect them against
the possibility that the IPO price might be less than their preferred stock price. Accordingly, Class A-1 Preferred Stock and Class A-2
Preferred Stock were created, and the holders of Class A were granted an opportunity to purchase shares of Common Stock at $0.40 per
share. If Class A stockholders purchased at least $6,000 of Common Stock, their shares of Class A Preferred Stock were exchanged for
shares of Class A-1 Preferred Stock which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and
if stockholders purchased a pro-rated amount of Common Stock, their shares of Class A Preferred Stock were exchanged for Class A-2 Preferred
Stock which in turn is convertible into shares of Common Stock at a discount of 10% to the IPO price. In all other respects the Class
A-1 Preferred Stock and Class A-2 Preferred Stock have the same rights and obligations as the Class A Preferred Stock. As of December
31, 2021, 1,437,500 shares of Class A Preferred Stock had been exchanged for Class A-1 Preferred Stock, and 2,212,500 shares of Class
A Preferred Stock had been exchanged for Class A-2 Preferred Stock, respectively, leaving outstanding 550,000 shares of Class A.
Class
B
There
are 9,000,000
shares of Class B Preferred Stock (“Class
B”) authorized designated at a par value of $0.01
per share. This designation includes Classes
B, B-1, B-2, and B-3. The Class B will be converted into shares of Common Stock upon listing of the Company on Nasdaq or NYSE. In the event
of any liquidation or winding up of the Company, the holders of the Class B shall be entitled to receive in preference to the holders
of Common Shares and Class A Preferred Stock, a per share amount equal to one times (1x) their original purchase price plus any declared
but unpaid dividends. The holders of Class B shall be entitled to receive dividends either first or simultaneously with dividends declared,
set apart or paid, on Junior Stock.
On
March 2, 2021, in preparation for an intended future IPO, the Company made an offer to all its preferred stockholders to protect them
against the possibility that the IPO price might be less than their preferred stock price. Accordingly, Class B-1 and Class B-2 Preferred
Stock (“Class B-1” and “Class B-2”, respectively) were created, and the holders of the Class B were granted an
opportunity to purchase shares of Common Stock at $0.40 per share. If stockholders purchased at least $6,000 of Common Stock, their Class
B were exchanged for Class B-1 which is guaranteed to convert into shares of Common Stock at the same price as the IPO price, and if
stockholders purchased a pro-rated amount of Common Stock their Class B were exchanged for Class B-2 which converts into shares of Common
Stock at a discount of 10% to the IPO price. The Class B-1 and B-2 accrue a dividend of 10% per annum payable only in the event of an
IPO or liquidation event in common stock assuming it was first converted into B-1 or B-2 as the case may be at the Original Issue Price.
In all other respects, the Class B-1 and Class B-2 have the same rights and obligations as the Class B. At December 31, 2021, 1,166,406
shares of Class B had been exchanged for Class B-1, and 2,176,250 shares of Class B had been exchanged for Class B-2, respectively, leaving
outstanding 286,250 shares of Class B. During the three and nine month periods ended December 31, 2021, the Company sold 2,176,250 and
4,458,750 shares of Class B-1 Preferred Stock for $1,741,000 and $3,567,001, respectively.
As
of December 31, 2021, the Company authorized 3,000,000 shares of Class B-3 Preferred (“Class B-3”). The Certificate of Designation
of the Class B-3 shares was filed with the Delaware Secretary of State on October 5, 2021. The Class B-3 will be offered for $0.80 per
share and have a cumulative dividend of 10% per annum payable only when as and if declared by the Board. The remaining terms and conditions
are substantially the same as for all other Class B shares, including mandatory conversion upon a majority vote of the Class B-3 stockholders,
closing of a qualified financing of at least $10 million, or listing on NYSE or NASDAQ. As of the date of this filing, the board of directors
has not declared any dividends.
B)
COMMON STOCK
The
Company has authorized 40,000,000 shares of common stock at a par value of $0.01 per share. As of December 31, 2021, and March 31, 2021
a total of 13,287,621 and 9,983,082 shares of the Company’s common stock were issued and outstanding, respectively.
During
the three and nine month periods ended December 31, 2021, in connection with the amendment of Preferred Stock rights described in A)
Preferred Stock above, the Company had sold zero
and 3,285,789
shares of Common Stock for $0
and $1,314,317,
of which $1,191,442
was received and accrued as subscription liability
at March 31, 2021.
During
each of the three and nine month periods ended December 31, 2021, the Company issued zero
and 18,750
shares of Common Stock for $0
and $618,
respectively, in connection with the exercise of stock options.
C)
STOCK OPTIONS
In
April 2018, the Board approved the introduction of the Kyto Technology and Life Science, Inc. Incentive Stock Option Plan (“the
2018 Plan”) reserving 2,697,085 shares for issuance to employees, consultants and directors, with the objective of securing the
benefit of services for stock options rather than cash salaries.
In
July 2019, the Board approved the introduction of the Kyto Technology and Life Science 2019 Stock Option and Incentive Plan (“2019
Plan”), and reserved 2 million shares for issuance to directors, officers, consultants, and advisors. Options granted under the
2019 Plan expire May 21, 2029.
In
December 2020, the Board approved the Kyto Technology and Life Science 2020 Non Qualified Stock Option Plan (“2020 Plan”),
and reserved 2 million shares for issuance to directors, officers, consultants and advisors. Options granted under the 2020 Plan expire
December 16, 2030. On December 20, 2021, the Board approved the creation of the 2021 Stock and Incentive Plan and reserved 2,000,000
shares of common stock as a pool for the grant of stock options.
During
the three months ended December 31, 2021, and December 31, 2020, the Company issued a total of 750,000
and 217,500
non-qualified stock options, respectively, to
consultants and advisors vesting over terms of two years. During the corresponding nine months ended December 31, 2021, and December
31, 2020, the Company issued a total of 2,290,000
and 847,500
non-qualified stock options, respectively.
SCHEDULE OF OPTIONS VESTED
| |
Number of options
granted | | |
Weighted average
exercise price | | |
Weighted average
remaining life
years | |
Outstanding March 31, 2021 | |
| 2,634,250 | | |
$ | 0.05 | | |
| 8.13 | |
Granted | |
| 2,290,000 | | |
| 0.07 | | |
| 9.67 | |
Exercised | |
| (18,750 | ) | |
| (0.03 | ) | |
| - | |
Cancelled | |
| - | | |
| - | | |
| - | |
Outstanding December 31, 2021 | |
| 4,905,500 | | |
$ | 0.06 | | |
| 8.71 | |
| |
| | | |
| | | |
| | |
Exercisable December 31, 2021 | |
| 2,791,705 | | |
$ | 0.05 | | |
| 8.90 | |
In
connection with the grant of stock options the Company recognizes the value of the related option expense using the Black Scholes model,
with appropriate assumptions for option life, stock value, risk free interest rate, volatility, and cancellations.
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
| |
December 31, 2021 | | |
March 31, 2021 | |
Stock Price at grant date | |
$ | 0.07 | | |
| $0.033 - $ 0.078 | |
Exercise Price | |
$ | 0.07 | | |
| $0.033 - $ 0.078 | |
Term in Years | |
| 0 - 2.00 | | |
| 0 - 2.00 | |
Volatility assumed | |
| 196 | % | |
| 71% - 196% | |
Annual dividend rate | |
| 0.0 | % | |
| 0.0 | % |
Risk free discount rate | |
| 0.12 | % | |
| 0.12% - 2.0% | |
The
compensation expense calculated at time of grant is recognized over the vesting period for the options granted. During the three and
nine months ended December 31, 2021, the Company recognized $32,579 and $54,033 respectively, as stock-based compensation expense. For
the corresponding three and nine months ended December 31, 2020, the Company recognized $3,474 and $17,326, respectively.
The
intrinsic value of outstanding options at December 31, 2021 was $62,580 and $56,987 of the option expense upon grant remained unrecognized
at December 31, 2021 with a remaining vesting period of 1.13 years.
D)
WARRANTS
In
conjunction with the sale of Class A Stock Units, the Company issued 4,200,000 warrants to purchase common stock at a price of $1.20
per share for a period of three years. The Company did not bifurcate the value of the warrants as the fair value of the warrant was determined
to be de minimis. The Company has not issued any warrants since September 2019. At December 31, 2021 and March 31, 2021 the fair value
of the warrants was de minimis.
SCHEDULE OF WARRANTS
| |
Number of
warrants | | |
Weighted average
exercise price | | |
Weighted average
remaining life in
years | |
Outstanding March 31, 2020 | |
| 4,200,000 | | |
$ | 1.20 | | |
| 2.9 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| (2,603,333 | ) | |
$ | 0.60 | | |
| - | |
Cancelled | |
| - | | |
| - | | |
| - | |
Outstanding December 31, 2020 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 2.2 | |
| |
| | | |
| | | |
| | |
Exercisable March 31, 2020 | |
| 4,200,000 | | |
$ | 1.20 | | |
| 2.9 | |
Exercisable December 31, 2020 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
| |
Number of warrants | | |
Weighted average exercise price | | |
Weighted average remaining life in years | |
Outstanding March 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
Granted | |
| - | | |
| - | | |
| - | |
Exercised | |
| - | | |
| - | | |
| - | |
Cancelled | |
| - | | |
| - | | |
| - | |
Outstanding December 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 0.6 | |
| |
| | | |
| | | |
| | |
Exercisable March 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 1.4 | |
Exercisable December 31, 2021 | |
| 1,596,667 | | |
$ | 1.20 | | |
| 0.6 | |
The
Company values the warrants using the Black Scholes model, with appropriate assumptions for warrant life, stock value, risk free interest
rate, and volatility. The assumptions used for warrant valuation were as follows:
SCHEDULE OF FAIR VALUE ASSUMPTIONS - STOCK OPTIONS
| |
December 31, 2021 | |
Stock Price at grant date | |
$ | 0.006 | |
Exercise Price | |
$ | 1.200 | |
Term in Years | |
| 3 | |
Volatility assumed | |
| 73 | % |
Annual dividend rate | |
| 0.0 | % |
Risk free discount rate | |
| 1.79 | % |
NOTE
7 – FINANCIAL HIGHLIGHTS
SCHEDULE OF FINANCIAL HIGHLIGHTS
Per share data (a) | |
Three months ended
December 31, 2021 | | |
Three months ended
December 31, 2020 | | |
Nine months ended
December 31, 2021 | | |
Nine months ended
December 31, 2020 | |
| |
| | |
| | |
| | |
| |
Net asset value | |
$ | 0.97 | | |
$ | 0.75 | | |
$ | 0.97 | | |
$ | 0.95 | |
| |
| | | |
| | | |
| | | |
| | |
Net investment loss | |
$ | (0.03 | ) | |
$ | (0.04 | ) | |
$ | (0.08 | ) | |
$ | (0.08 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net unrealized gain on investments | |
$ | 0.05 | | |
$ | 0.04 | | |
$ | 0.16 | | |
$ | 0.12 | |
| |
| | | |
| | | |
| | | |
| | |
Net increase in net assets | |
$ | 0.02 | | |
$ | - | | |
$ | 0.07 | | |
$ | 0.04 | |
| |
| | | |
| | | |
| | | |
| | |
Ratios and Supplemental Data | |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
Net assets, end of period | |
$ | 12,911,623 | | |
$ | 6,399,543 | | |
$ | 12,911,623 | | |
$ | 6,399,543 | |
| |
| | | |
| | | |
| | | |
| | |
Weighted average common shares outstanding, end of period | |
| 13,287,621 | | |
| 8,528,007 | | |
| 13,273,038 | | |
| 6,737,152 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses/net assets | |
| 2.9 | % | |
| 5.2 | % | |
| 8.6 | % | |
| 8.3 | % |
| |
| | | |
| | | |
| | | |
| | |
Net investment loss/net assets | |
| (2.9 | )% | |
| (5.2 | )% | |
| (8.6 | )% | |
| (8.3 | )% |
| |
| | | |
| | | |
| | | |
| | |
Total return | |
| 2.5 | % | |
| (0.1 | )% | |
| 7.6 | % | |
| 4.3 | % |
NOTE
8 - SUBSEQUENT EVENTS
Subsequent
to February 21, 2021, the Company has collected more than $800,000
from the sale of stock since December 31, 2021,
and spent $400,000
on new investments.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIONS AND RESULTS OF OPERATIONS
PLAN
OF OPERATIONS
Kyto
Technology and Life Science, Inc. (the “Company”) was formed as a Florida corporation on March 5, 1999 under the name of
B Twelve, Inc. In August, 2002, the Company changed its name from B Twelve, Inc. to Kyto BioPharma Inc. and in May 2018, the name was
changed again to Kyto Technology and Life Science, Inc. In July 2019, the Company was re-incorporated as a Delaware company. The Company
operates virtually, from public locations or the homes of its officers, and does not currently lease any office space.
The
Company was originally formed to acquire and develop proprietary drugs for the treatment of cancer, arthritis, and other autoimmune diseases
and had been evaluating a number of strategies. In April 2018, the Board adopted a new business plan focused on the development of early-stage
technology and life science businesses through early stage investment funding. The Company has recruited a number of experienced investment
consultants from a network that includes angel investors, corporate managers, sophisticated early stage investors and successful entrepreneurs
with experience across a number of technology and life science products and markets, and relies on input from these advisors in conducting
due diligence and making investment decisions. In order to offset the risk in early-stage investing, the Company works with angel investment
groups and other sophisticated investors and participates only after these groups have completed due diligence and committed to invest,
in effect becoming lead investors. The Company then completes its own due diligence and invests under identical terms as the lead investors.
The Company will do follow-on investments in existing portfolio companies, assuming adequate progress, when portfolio companies initiate
new financing rounds. The Company currently does not typically invest more than $250,000 in any single investment. Generally, the Company’s
investments represent less than 5% ownership interests, and the Company therefore has no effective control or influence over the management
or commercial decisions of the companies in which it invests. The Company plans to generate revenue from realized gains from the sale
of the businesses in which it has invested, or some or all of its shareholdings in those cases where portfolio companies go public. Generally,
it is expected that investments will be realized from an exit within a period of four to five years following initial investment. Such
exits or liquidity events are outside the Company’s control and depend on merger and acquisition (“M&A”) transactions
or an initial public offering (“IPO”) which may result in cash or equity proceeds. Accordingly, it is difficult to forecast
revenue, net income, and cash flow. Other than making its initial and, potentially, follow-on investments in its portfolio companies,
the Company does not provide any financial support to any of its investees.
The
Company has one regular employee – the CEO, Mr, Paul Russo. Prior to December 31, 2020, he was acting as a consultant to
the Company and did not receive contractual compensation for his services in the form of cash. As of January 1, 2021, Mr. Russo was engaged
as an employee of the Company at a salary of $400,000 per annum of which $100,000 and $300,000 was earned in the three months and
nine months ended December 31, 2021, respectively, of which a balance of $80,000 was deferred at December 31, 2021. No consulting
fees and no options were granted to him during these periods. During the three months and nine months ended December 31, 2020, Mr. Russo
received no payroll or consulting fees, however in the three and nine months ended December 31, 2020, he received a bonus of $50,000
and was granted options to purchase 215,000 shares of Common stock.
The
Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the
sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result
in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of December 31, 2021,
the Company had approximately $600,000 of cash to cover its operating expenses, and new investment requirements, and is continuing
to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and
ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on
attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about
the Company’s ability to continue as a going concern. Stay at home orders and general economic uncertainties arising out of the
current Covid-19 epidemic have created additional delays and uncertainty. To date there has been no disruption to the Company’s
business operations, although some of its portfolio investment companies report delays in their programs.
At
March 31, 2020, management determined that the Company was an investment company for purposes of ASC 946 disclosure, and committed to
follow the specialized accounting and reporting guidance contained therein. Accordingly, a new company, Kyto Investments, Inc. (“KI”)
was incorporated in Delaware in December 2020 in preparation for a restructuring and an N-2 Registration Statement filed in March 2021
for review by the SEC. KI is an internally managed, closed-end investment company that has elected to be regulated as a business development
company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). Immediately upon effectiveness
of this N-2 Registration Statement, the Company will merge with KI and the Company will be the surviving entity. As of the completion
of the merger, the Company will constitute a “successor issuer” for the purposes of Rule 414 under the Securities Act and
may continue the current offering by filing post-effective amendments to the Registration Statements. Prior to the merger, the Company
had fewer than 100 non-affiliated investors and filed under the 1934 Act relying on exemption Rule 3( c )(1).
As
a BDC, the Company will be required to comply with certain regulatory requirements. The Company also intends to elect to be treated for
U.S. federal income tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Internal Revenue Code
of 1986, as amended (the “Code”). As a RIC, the Company is required to comply with additional regulatory requirements. The
Company has prepared and submitted sequentially two N-2 Registration Statements to the SEC for review but has not yet received final
approval of its registration as at the filing date of this report.
Results
of Operations
Revenue:
In the three months and nine months ended December 31, 2021 the Company reported no realized investment income as there were no liquidity
events related to its investment portfolio. The Company reported $691,864 and $2,095,180 of net change in unrealized gains from investments
respectively, in these periods. In the three months and nine months ended December 31, 2020 the Company reported no realized investment
income as there were no liquidity events related to its investment portfolio. The Company reported $328,694 and $806,942 of net change
in unrealized gains from investments respectively, in these same periods.
Professional
fees: In the three months and nine months ended December 31, 2021, the Company reported $98,241 and $371,600, respectively, of professional
fees, mainly for legal and accounting services. In the corresponding three months and nine months ended December 31, 2020 the Company
reported $91,669 and $168,212, respectively.
Other
operating expenses: Other operating expenses include payroll, consulting, and travel and conference fees associated with raising capital
and review of investment deal-flow. In the three months and nine months ended December 31, 2021, the Company incurred other operating
expenses of $273,473 and $741,089, respectively. In the corresponding three months and nine months ended December 31, 2020, the Company
incurred other operating expenses of $241,047 and $363,983, respectively.
For
the three months and nine months ended December 31, 2021, the Company’s net increase in net assets resulting from operations was
$188,151 and $499,798, respectively. For the corresponding three months and nine months ended December 31, 2020, the Company’s
net increase (decrease) in net assets resulting from operations was ($4,017) and $275,252, respectively.
During
the three and nine months ended December 31, 2021, the Company was subject to shelter in place regulations imposed by the State of California
in mitigation of the spread of the Corona 19 virus. Since the Company does not have any dedicated office space and works virtually from
the homes of its officers, there was no major disruption in working routines which continued by video and teleconference. Uncertainty
arising from Covid 19 created a slow-down in the rate at which the Company was able to raise Class B funding, and thereby continue to
make investments, however the Company did see a reduction in travel and investor relations expenses during the period. The Company has
more than 60 discrete investments in a range of different industry and geographic segments, many of which are in the life science and
medical space. While there is clearly a risk that our portfolio companies may be adversely affected in their ability to raise future
funding or do business, there have been no management reports revealing major problems and some of our portfolio companies may actually
benefit from new opportunities created. We believe that our policy of spreading our investments in relatively small amounts over a large
number of portfolio companies helps mitigate some of the risk that might be suffered by any of our investments.
Liquidity,
Capital Resources and Going Concern
The
Company had net assets of $12,911,623 and $6,993,163 at December 31, 2021 and March 31, 2021, respectively. Cash was $608,223 and $1,437,868
at December 31, 2021 and March 31, 2021, respectively.
The
Company’s condensed interim financial statements are prepared in accordance with U.S. GAAP, which requires the use of
estimates, assumptions and the exercise of subjective judgment as to future uncertainties. Actual results could differ from those
estimates, assumptions, and judgments. Significant items subject to such estimates will include determining the fair value of
investments, revenue recognition, income tax uncertainties, stock-based compensation, and other contingencies.
The
Company has created a portfolio of minority investments in early-stage start-up companies and derives its revenue opportunity from the
sale of those investments. Such sales are outside the Company’s control and depend on M&A transactions or IPOs which may result
in cash or equity proceeds. Accordingly, it is difficult to forecast revenue, net income, and cash flow. As of December 31, 2021,
the Company had approximately $600,000 of cash to cover its operating expenses, and new investment requirements and is continuing
to raise additional funding on a recurring monthly basis. If successful, it will have sufficient funding for further investments and
ongoing operations. However, there is no assurance that the Company will be able to raise sufficient cash to cover its requirements on
attractive terms, if at all, and whether it will be able to continue as a going concern. These conditions raise substantial doubt about
the Company’s ability to continue as a going concern. The accompanying condensed interim financial statements have been prepared
assuming the Company will continue to operate as a going concern and do not include any adjustments that might result from the outcome
of this uncertainty. Stay at home orders and general economic uncertainties arising out of the current Covid-19 epidemic have created
additional delays and uncertainty. To date there has been no disruption to the Company’s business operations, although some of
its portfolio investment companies report delays in their programs.
Cash
from operating activities
The
Company used net cash of $4,520,139 in operating activities during the nine months ended December 31, 2021 compared to $2,876,156 used
for the nine months ended December 31, 2020. The main reasons for the higher level in 2021 were an increase in investments in portfolio
companies and increased professional fees and operating expenses.
Cash
from investing activities
No
cash was used in investing activities.
Cash
from financing activities
The
Company had a net cash inflow from financing activities of $3,690,494 in the nine months ended December 31, 2021 compared to $3,406,195
in the nine months ended December 31, 2020. This inflow included $3,567,001 proceeds from the sale of Class B preferred stock (including
B-1 and B-3), and $122,875 proceeds from the sale of common stock, respectively, in the nine months ended December 31, 2021, compared
to $1,873,125 from the sale of Class B preferred stock, and $1,566,229 proceeds from the sale of common stock, respectively, in the corresponding
nine month prior period ended December 31, 2020.
The
Company’s plan of operations for the next twelve months is to continue to focus its efforts on finding new sources of capital by
means of private placements, and to use this capital to fund additional investments as they become available, and to cover operating
expenses. The Company is planning to uplift from OTC to the NASDAQ market, and raise additional funding from an initial public offering
(“IPO)” for which as an initial step it has submitted an N-2 filing to the SEC for review.
CRITICAL
ACCOUNTING POLICIES
USE
OF ESTIMATES
In
preparing financial statements, management is required to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during
the period presented. Actual results may differ from these estimates.
Significant
estimates at December 31, 2021 and March 31, 2021 include the valuation of investments, deferred tax assets, tax allowance, stock options
and warrants.
INVESTMENT
AND VALUATION OF INVESTMENT AT FAIR VALUE
The
Company reviews the performance of its investments based on available information, including management reports, press releases, web
site announcements and progress reports, third party equity updates, management interviews and, where accessible, financial reports,
to determine their fair values. In the event that Management considers the fair value of an investment to be greater or less than the
current book value, the difference will be reflected as unrealized gains or losses in investments in the statements of operations.
The
Company adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820,
“Fair Value Measurements and Disclosures”, for assets and liabilities measured at fair value on a recurring basis. ASC
820 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements which
establishes a framework for measuring fair value and expands disclosure about such fair value measurements.
Fair
value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between
market participants. Fair value is an exchange price notion under which fair value is the price in an orderly transaction between market
participants to sell an asset or transfer a liability in the market in which the reporting entity would transact for the asset or liability.
The
Company has established procedures to estimate the fair value of its investments which the Company’s board of directors has reviewed
and approved. The Company uses observable market data to estimate the fair value of investments to the extent that market data is available.
In the absence of quoted market prices in active markets, or quoted market prices for similar assets or in markets that are not active,
the Company uses the valuation methodologies described below with unobservable data based on the best available information in the circumstances,
which incorporates the Company’s assumptions about the factors that a market participant would use to value the asset.
For
investments for which quoted market prices are not available, which comprise most of our investment portfolio, fair value is estimated
by using the income, market, or back-solve approach. The income approach is based on the assumption that value is created by the expectation
of future benefits discounted to a current value and the fair value estimate is the amount an investor would be willing to pay to receive
those future benefits. The market approach compares recent comparable transactions to the investment. The back solve method involves
comparing available data over a period of time and inferring a new valuation based on changes from a known starting point, for example
the cost of an investment. Adjustments are made for any dissimilarity between the comparable transactions and the investments. These
valuation methodologies involve a significant degree of judgment on the part of our management and board.
In
determining the appropriate fair value of an investment using these approaches, the most significant information and assumptions may
include, as applicable: available current market data, including relevant and applicable comparable market transactions, applicable market
yields and multiples, security covenants, call protection provisions, information rights, the nature and realizable value of any collateral,
the investment’s ability to make payments, its earnings and discounted cash flows, the markets in which the company does business,
comparisons of financial ratios of peer companies that are public, merger and acquisition comparables, the principal market and enterprise
values, environmental factors, subsequent financings by the portfolio investment, among other factors.
The
estimated fair values do not necessarily represent the amounts that may be ultimately realized due to the occurrence or nonoccurrence
of future circumstances that cannot be reasonably determined. Because of the inherent uncertainty of the valuation of the investments,
the estimate of fair values may differ significantly from the value that would have been used had a broader market for the investments
existed.
RECENT
ACCOUNTING PRONOUNCEMENTS
Management
does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect
on the accompanying financial statements.
OFF-BALANCE
SHEET ARRANGEMENTS
As
of the date of this Quarterly Report on Form 10-Q, we do not have any off-balance sheet arrangements that have or are reasonably likely
to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations,
liquidity, capital expenditures or capital resources that are material to investors.
IMPACT
OF INFLATION
The
Company does not foresee any implications being created by the current rate of inflation.
CONTRACTUAL
OBLIGATION
The
Company has no contractual obligations outside the normal course of business with its vendors, advisors, and consultants.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not
required for smaller reporting company.
ITEM
4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
We
maintain disclosure controls and procedures that are designed to ensure that material information required to be disclosed in our periodic
reports filed under the Securities Exchange Act of 1934, as amended, or 1934 Act, is recorded, processed, summarized, and reported within
the time periods specified in the SEC’s rules and forms and to ensure that such information is accumulated and communicated to
our management, including our chief executive officer/chief financial officer (principal financial officer) as appropriate, to allow
timely decisions regarding required disclosure. During the three months ended December 31, 2021 we carried out an evaluation, under the
supervision and with the participation of our management, including the principal executive officer and the principal financial officer
(principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures, as defined
in Rule 13(a)-15(e) under the 1934 Act. Based on this evaluation, because of the Company’s limited resources and limited number
of employees, management concluded that our disclosure controls and procedures were ineffective as of December 31, 2021. Notwithstanding
this conclusion, we believe that our unaudited condensed financial statements contained in this Quarterly Report fairly present our financial
position, results of operations and cash flows for the periods covered thereby in all material respects.
Management’s
Report on Internal Control over Financial Reporting
With
the participation of our Chief Executive Officer and Chief Financial Officer (principal financial officer), our management conducted
an evaluation of the effectiveness of our internal control over financial reporting as of December 31, 2021 based on the framework in
Internal Controls—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”).
Based on our evaluation and the material weaknesses described below, management concluded that the Company did not maintain effective
internal control over financial reporting as of December 31, 2021 based on the COSO framework criteria. Management has identified control
deficiencies regarding the lack of segregation of duties and the need for a stronger internal control environment. Management of the
Company believes that these material weaknesses are due to the small size of the Company’s accounting staff. The small size of
the Company’s accounting staff may prevent adequate controls in the future, such as segregation of duties, due to the cost/benefit
of such remediation. To mitigate the current limited resources and limited employees, we rely heavily on direct management oversight
of transactions, along with the use of external legal and accounting professionals. As we grow, we expect to increase our number of employees,
which will enable us to implement adequate segregation of duties within the internal control framework. In addition, we have identified
the following material weaknesses: (i) the Company utilizes accounting software that does not prevent erroneous or unauthorized changes
to previous reporting periods and/or can be adjusted so as not to provide an adequate audit trail of entries made in the accounting software,
and (ii) we have identified a material weakness in our internal controls relating to the accounting of transactions that are either highly
complex and/or unusual in nature.
During the quarter ended December 31,
2021, we discovered our internal control over financial reporting did not result in the proper accounting for earnings per share for
the three months ended June 30, 2021 and the three and six months ended September 30, 2021, which we determined to be a material weakness.
Accordingly, we have determined that these control deficiencies as described above together constitute a material weakness. However,
management believes that despite our material weaknesses, our financial statements for the three and nine month periods ended December
31, 2021 are fairly stated, in all material respects, in accordance with U.S. GAAP.
Limitations
on Effectiveness of Controls and Procedures
Our
management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), does not expect that our
disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well
conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further,
the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered
relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance
that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include, but
are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or
by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the
likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential
future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies
or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.
PART
II. OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
None
ITEM
1A. RISK FACTORS.
Not
required for smaller reporting company.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The
Company has issued certificates of designation for up to 9 million shares of Series B-1, B-2, and B-3 of which 8,087,656 were subscribed
through December 31, 2021.
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM
4. MINE SAFETY DISCLOSURES
Not
applicable
ITEM
5. OTHER INFORMATION
None
ITEM
6. EXHIBITS
Index
to Exhibits on page 13
INDEX
TO EXHIBITS
* |
Filed
as Exhibit to Company’s Form 10-SB on September 12, 2003 with the Securities and Exchange Commission. |
** |
Previously
filed with Form 8-K on July 17, 2019. |
*** |
Filed
as Exhibit with Form 10-K on July 2, 2020. |
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
Kyto Technology and Life Science, Inc.
|
|
|
|
|
By: |
/s/ Paul
Russo |
|
|
Paul Russo |
|
|
Chief Executive Officer, principal executive officer, |
|
|
|
Date: February 22, 2022 |
|
|
SIGNATURES
In
accordance with the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.
|
Kyto Technology and Life Science, Inc.
|
|
|
|
|
By: |
/s/ Simon
Westbrook |
|
|
Simon Westbrook |
|
|
Principal financial and accounting officer |
|
|
|
Date: February 22, 2022 |
|
|